RESULT_COUNT: 506,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
BLUE,BLUE:UW,BBG004KB4FS6,"Celgene Could Be the Best CAR-T Stock to Buy, Not Gilead Sciences",2017-10-20 11:31:00 +0000,https://finance.yahoo.com/news/celgene-could-best-car-t-113100536.html?.tsrc=rss,Celgene&apos;s partnership strategy gives it exposure to multiple companies&apos; research on next-generation cell therapy.
BLUE,BLUE:UW,BBG004KB4FS6,Does Gilead Now Have A New Multi-Billion-Dollar Franchise?,2017-10-19 20:48:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p7Athhyn3y0/does-gilead-now-have-a-new-multi-billion-dollar-franchise-cm861865,Gilead Sciences GILD jumped early Thursday after the Food and Drug Administration approved what is known as a CAR T drug dubbed Yescarta to treat an aggressive form of non Hodgkin lymphoma ibd display video id 2381354 width 50 float left autostart true The late
BLUE,BLUE:UW,BBG004KB4FS6,Celgene Blood Cancer Treatment: Just The Tip Of Its Disruptive Science?,2017-10-17 21:51:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CEItNXh7o0I/celgene-blood-cancer-treatment-just-the-tip-of-its-disruptive-science-cm859983,Celgene CELG a pioneer and leading player in blood cancer treatment has become a biotech juggernaut thanks largely to a drug that proved key in fighting the tricky disease multiple myeloma ibd display video id 2326965 width 50 float left autostart true In multiple
BLUE,BLUE:UW,BBG004KB4FS6,"HIIQ In Good Health, BOLD Awaits ASPIRO Data, CELESTIAL Lights Up EXEL",2017-10-16 21:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4hhrQ3h8PGQ/hiiq-in-good-health-bold-awaits-aspiro-data-celestial-lights-up-exel-20171016-01420,"HIIQ In Good Health, BOLD Awaits ASPIRO Data, CELESTIAL Lights Up EXEL"
BLUE,BLUE:UW,BBG004KB4FS6,Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field,2017-10-16 13:18:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I9RrLF1kayM/kite-pharma-cancer-treatment-stands-out-in-hot-car-t-field-cm859985,Kite Pharma is edging closer to approval for a cutting edge cancer treatment that fights the disease by rebuilding a patient s own cells 160 a technology that could benefit thousands of people and pave the way for blockbuster drugs ibd display video id 2326965 width 50 float
BLUE,BLUE:UW,BBG004KB4FS6,Buying And Selling Stocks Right Are Keys To This Top Mutual Fund's Success,2017-10-16 13:18:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lW-8hJhOEQA/buying-and-selling-stocks-right-are-keys-to-this-top-mutual-funds-success-cm859982,Victory RS Small Cap Growth Fund RSEGX has been a dominant force among small growth stock funds in 2017 RS Investments chief investment officer Scott Tracy and his team have delivered a stellar performance with a focus on risk adjusted returns Mr Tracy comanages the 1 6
BLUE,BLUE:UW,BBG004KB4FS6,Today's Research Reports on Stocks to Watch: MannKind Corporation and Bluebird Bio,2017-10-12 12:10:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000367.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / October 12, 2017 / MannKind and bluebird bio both dipped into red territory on Wednesday. Despite no negative news from bluebird, shares still sank nearly 5%. Shares of Mannkind, ..."
BLUE,BLUE:UW,BBG004KB4FS6,"IWM, BLUE, STL, AZPN: ETF Outflow Alert",2017-10-10 17:10:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kYf6x6GzO4c/iwm-blue-stl-azpn-etf-outflow-alert-cm857625,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 2000 ETF Symbol IWM where we have detected an approximate 255 1 million dollar outflow that s a 0 6 decrease week over week from 277 800
BLUE,BLUE:UW,BBG004KB4FS6,Why CRISPR Therapeutics AG Stock Lost Ground in September,2017-10-10 15:14:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QTGam1ti-IY/why-crispr-therapeutics-ag-stock-lost-ground-in-september-cm857463,What happened According to data from S amp P Global Market Intelligence shares of the gene editing company CRISPR Therapeutics NASDAQ CRSP dropped by 13 1 in September CRISPR s poor showing last month appears to stem from nothing more than investors simply shifting
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Chardan Gene Therapy Conference,2017-10-06 20:16:00 +0000,https://finance.yahoo.com/news/bluebird-bio-present-chardan-gene-201600631.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the Chardan Gene Therapy Conference on Tuesday, October 10, 3:00 pm ET at the Westin Grand Central, New York City."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine,2017-10-04 19:00:00 +0000,https://finance.yahoo.com/news/bluebird-bio-announces-publication-interim-190000886.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from an initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study evaluating Lenti-D™ investigational gene therapy in boys with cerebral adrenoleukodystrophy were published ..."
BLUE,BLUE:UW,BBG004KB4FS6,Analysts Act on Health Care Stocks,2017-10-04 11:53:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2vOBEp3EP-4/analysts-act-on-health-care-stocks-cm854988,Analysts have taken action on some health care stocks Analysts have taken action on some health care stocks Among the health care companies that saw their stocks re rated by investment banking and financial services companies are AbbVie ABBV and two mid caps bluebird bio BLUE
BLUE,BLUE:UW,BBG004KB4FS6,"Why bluebird bio, Inc. Stock Gained 10% in September",2017-10-03 14:42:00 +0000,http://finance.yahoo.com/r/ac489f4c-ad0c-3b68-b4f6-1d2695b54d3a/why-bluebird-bio-inc-stock-gained-10-in-september.aspx?yptr=yahoo&.tsrc=rss,Another licensing deal with an important partner bodes well for the clinical-stage biotech.
BLUE,BLUE:UW,BBG004KB4FS6,Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing,2017-10-02 20:48:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qCaFqfJamf0/why-bluebirds-downgrade-sent-these-two-rivals-skyrocketing-cm854190,Bluebird Bio BLUE toppled to a four week low Monday 160 as an analyst downgraded the stock on doubts regarding its sickle cell disease drug 160 sending shares of rivals Crispr Therapeutics CRSP and Editas Medicine EDIT
BLUE,BLUE:UW,BBG004KB4FS6,Why Bluebird&apos;s Downgrade Sent These Two Rivals Skyrocketing,2017-10-02 20:10:03 +0000,http://finance.yahoo.com/r/eda14fae-3cce-3a4d-a18f-dbd74a86cec2/bluebird-downgrade-sent-crispr-editas-stock-skyrocketing?src=A00220&yptr=yahoo&.tsrc=rss,Bluebird toppled to a four-week low Monday as an analyst downgraded the stock on doubts regarding its sickle cell disease drug.
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio: So Much for That Gilead Boost,2017-10-02 19:56:00 +0000,http://finance.yahoo.com/r/7ffe85c6-5d44-3a05-8ed7-4a34596036cc/bluebird-bio-so-much-for-that-gilead-boost-1506974212?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"When Gilead Sciences (GILD) announced its acquisition of Kite Pharma (KITE), every company that had exposure to CAR-T --a type of cancer therapy that could allow for the creation of personalized drugs--got ..."
BLUE,BLUE:UW,BBG004KB4FS6,Here's Why Bluebird Bio (BLUE) Stock Is Falling Today,2017-10-02 17:46:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yT5eEkQXjNs/heres-why-bluebird-bio-blue-stock-is-falling-today-cm854044,Shares of Bluebird Bio BLUE a major player in the emerging gene therapy and CAR T research markets slumped more than 6 in morning trading Monday after receiving a key analyst downgrade In a note to clients Morgan Stanley downgraded the biotech firm from Equal weight to Underweight
BLUE,BLUE:UW,BBG004KB4FS6,"IWM, RFAP: Big ETF Outflows",2017-10-02 16:49:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GSLbaSdrI64/iwm-rfap-big-etf-outflows-cm853998,Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel the biggest outflow was seen in the iShares Russell 2000 ETF IWM where 7 550 000 units were destroyed or a 2 6 decrease week over week Among the largest underlying components of IWM
BLUE,BLUE:UW,BBG004KB4FS6,Here&apos;s Why Bluebird Bio (BLUE) Stock Is Falling Today,2017-10-02 16:00:04 +0000,https://finance.yahoo.com/news/apos-why-bluebird-bio-blue-160004488.html?.tsrc=rss,"Shares of Bluebird Bio (BLUE), a major player in the emerging gene therapy and CAR-T research markets, slumped more than 6% in morning trading Monday after receiving a key analyst downgrade."
BLUE,BLUE:UW,BBG004KB4FS6,"Morning Movers: Sarepta Jumps, Bluebird Bio Drops, MGM Slumps",2017-10-02 14:46:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tHcrtGeIWuQ/morning-movers-sarepta-jumps-bluebird-bio-drops-mgm-slumps-cm853815,Stocks look set for a higher open this morning despite a shooting in Las Vegas as China s official purchasing managers index rose to its highest level since 2012 Stocks look set for a higher open this morningdespite a shooting in Las Vegas asChina sChina s official purchasing
BLUE,BLUE:UW,BBG004KB4FS6,Featured Company News - Bluebird Bio Declares Treatment of 1st Patient with 2nd Anti-BCMA CAR T bb21217 in CRB-402 Phase-1 Study,2017-10-02 11:40:00 +0000,https://finance.yahoo.com/news/featured-company-news-bluebird-bio-114000126.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / October 2, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Bluebird Bio, Inc. (NASDAQ: BLUE ), following which we have published ..."
BLUE,BLUE:UW,BBG004KB4FS6,Big Dose Of Healthy News Sends Biotech Stocks To New Heights,2017-09-29 20:35:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3FWQwxHomzs/big-dose-of-healthy-news-sends-biotech-stocks-to-new-heights-cm853272,Biotech news aplenty has breathed renewed life into the sector driving 160 those stocks to new highs ibd display video id 2324623 width 50 float left autostart true Zogenix ZGNX on Friday spiked more than 140 nearing a four year high after reporting positive Phase
BLUE,BLUE:UW,BBG004KB4FS6,Why Biotech and Tech Will Push Stocks Higher In 4Q,2017-09-29 14:54:00 +0000,http://finance.yahoo.com/r/7401e074-5696-3c53-a9d6-89edc9f17f89/why-biotech-and-tech-will-push-stocks-higher-4q?partner=YahooSA&yptr=yahoo&.tsrc=rss,"The tech and biotech sectors have buoyed the broader market this year, and they're not letting up anytime soon."
BLUE,BLUE:UW,BBG004KB4FS6,"Morning Movers: Conn's Climbs, JB Hunt Soars, Goldcorp Gains",2017-09-29 14:33:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E_DFPxYL9Vc/morning-movers-conns-climbs-jb-hunt-soars-goldcorp-gains-cm853029,Stocks looks set for a mixed open this morning as September normally the market s worst month looks set to close with solid gains Stocks looks set for a mixed open this morning as September normally the market s worst month looks set toclose with solid gains
BLUE,BLUE:UW,BBG004KB4FS6,Should You Be Concerned About bluebird bio Inc’s (BLUE) Risks?,2017-09-29 12:37:08 +0000,https://finance.yahoo.com/news/concerned-bluebird-bio-inc-blue-123708359.html?.tsrc=rss,"For bluebird bio Inc’s (NASDAQ:BLUE) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. The beta measuresRead More..."
BLUE,BLUE:UW,BBG004KB4FS6,"Why BlackBerry, AbbVie, and bluebird bio Jumped Today",2017-09-28 22:35:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Tf9GqBj_mGY/why-blackberry-abbvie-and-bluebird-bio-jumped-today-cm852882,Thursday was a quiet day on Wall Street with major benchmarks remaining close to the unchanged level Sentiment among market participants remained relatively favorable in the aftermath of the release of the Trump administration s tax reform proposal although a closer look at the
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Hits High On Bullish Report Highlighting Blood Drugs,2017-09-28 21:33:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5o9fy8Hv5g8/bluebird-hits-high-on-bullish-report-highlighting-blood-drugs-cm852795,Bluebird Bio BLUE rocketed to a two year high Thursday on an analyst s bullish report outlining the biotech s blood disease pipeline that includes a tie up with No 2 biotech Celgene CELG ibd display video id 2323827 width 50 float left autostart true By
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Hits High On Bullish Report Highlighting Blood Drugs,2017-09-28 20:57:42 +0000,http://finance.yahoo.com/r/ca925682-2d5b-39e2-aa4d-e12ace212fa7/bluebird-hits-high-on-bullish-report-highlighting-blood-drugs?src=A00220&yptr=yahoo&.tsrc=rss,Bluebird rocketed to a two-year high Thursday on an analyst&apos;s bullish report outlining the biotech&apos;s blood-disease pipeline.
BLUE,BLUE:UW,BBG004KB4FS6,"Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio",2017-09-28 20:36:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yV5ivAKVRns/better-buy-bellicum-pharmaceuticals-inc-vs-bluebird-bio-cm852798,This version of our ongoing better buy series pits two development stage biotechs Bellicum Pharmaceuticals NASDAQ BLCM and bluebird bio NASDAQ BLUE against each other The companies have something in common they re both developing chimeric antigen receptor T cell CAR
BLUE,BLUE:UW,BBG004KB4FS6,"Why BlackBerry, AbbVie, and bluebird bio Jumped Today",2017-09-28 20:30:00 +0000,http://finance.yahoo.com/r/e6518926-5fd2-3ccb-97ba-a0d113a4c1ac/why-blackberry-abbvie-and-bluebird-bio-jumped-toda.aspx?yptr=yahoo&.tsrc=rss,"On a mildly positive day for the market, these stocks climbed. Find out why."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma,2017-09-28 20:05:00 +0000,https://finance.yahoo.com/news/bluebird-bio-announces-first-patient-200500166.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, announced the treatment of the first patient with relapsed/refractory multiple myeloma in a Phase 1 study of bb21217."
BLUE,BLUE:UW,BBG004KB4FS6,"Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio",2017-09-28 18:38:00 +0000,http://finance.yahoo.com/r/ccb2eabd-90c0-38b5-964b-2f9fccf19646/better-buy-bellicum-pharmaceuticals-inc-vs-bluebir.aspx?yptr=yahoo&.tsrc=rss,There&apos;s more than meets the eye to both of these CAR-T biotechs.
BLUE,BLUE:UW,BBG004KB4FS6,Stock Indexes Mixed; Small Caps Lag,2017-09-28 17:41:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p9mv6QwwQcg/stock-indexes-mixed-small-caps-lag-cm852691,U S stock indexes took small steps in mixed action midday Thursday a day after scoring big gains The Nasdaq lost 0 2 at midsession Thursday while the S amp P 500 was flat The Dow Jones industrial average inched up 0 1 The small cap Russell 2000 carved off 0
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Inc. (BLUE) Has Broken Out To A New High For The Year,2017-09-28 10:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jNQz1nJts-U/bluebird-bio-inc-blue-has-broken-out-to-a-new-high-for-the-year-20170928-00822,Bluebird Bio Inc. (BLUE) Has Broken Out To A New High For The Year
BLUE,BLUE:UW,BBG004KB4FS6,3 Biotech Stocks With Major Catalysts in October,2017-09-26 13:52:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jrCSOvFQb3s/3-biotech-stocks-with-major-catalysts-in-october-cm850928,Every month brings plenty of catalysts for several biotech stocks October is no exception There are quite a few regulatory decisions and clinical results expected to be announced next month Three biotechs in particular could enjoy boosts to their stocks if all goes well Here are
BLUE,BLUE:UW,BBG004KB4FS6,3 Biotech Stocks With Major Catalysts in October,2017-09-26 13:32:00 +0000,http://finance.yahoo.com/r/8565200c-db91-3665-a6ed-d3a832666fe5/3-biotech-stocks-with-major-catalysts-in-october.aspx?yptr=yahoo&.tsrc=rss,These biotechs are hoping that October brings blue skies for their promising pipeline candidates.
BLUE,BLUE:UW,BBG004KB4FS6,"IWM, ESGU: Big ETF Inflows",2017-09-22 16:39:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U8gOXl6F6-o/iwm-esgu-big-etf-inflows-cm849688,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the iShares Russell 2000 ETF which added 15 150 000 units or a 5 6 increase week over week Among the largest underlying components of IWM in morning trading
BLUE,BLUE:UW,BBG004KB4FS6,Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?,2017-09-22 15:41:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NrIOSO31NmU/juno-therapeutics-inc-juno-stock-to-buy-or-not-to-buy-cm849713,InvestorPlace Stock Market News Stock Advice amp Trading Tips It s been a great summer for 160 Juno Therapeutics Inc NASDAQ JUNO JUNO stock is up 50 over the past month and has more than doubled year to date It s been quite the reversal of
BLUE,BLUE:UW,BBG004KB4FS6,Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?,2017-09-22 11:03:58 +0000,https://finance.yahoo.com/news/juno-therapeutics-inc-juno-stock-110358957.html?.tsrc=rss,"It’s been a great summer for Juno Therapeutics Inc (NASDAQ:JUNO).  JUNO stock is up 50% over the past month and has more than doubled year-to-date.  It’s been quite the reversal of fortunes after a rough period that saw JUNO stock reach $70 in 2015, then plummet to $20, as investors lost faith in its CAR-T platform."
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors",2017-09-20 12:00:00 +0000,https://finance.yahoo.com/news/bluebird-bio-appoints-mary-lynne-120000126.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has appointed Mary Lynne Hedley, Ph.D."
BLUE,BLUE:UW,BBG004KB4FS6,"Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade",2017-09-19 15:35:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q8fAs25q_ko/yes-juno-therapeutics-juno-just-became-a-great-car-t-trade-cm847784,InvestorPlace Stock Market News Stock Advice amp Trading Tips Juno Therapeutics Inc NASDAQ JUNO is poised to benefit from a rising acquisition trend Three weeks ago when Gilead Sciences Inc NASDAQ GILD announced it would
BLUE,BLUE:UW,BBG004KB4FS6,"Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade",2017-09-19 11:09:37 +0000,https://finance.yahoo.com/news/yes-juno-therapeutics-juno-just-110937168.html?.tsrc=rss,"Juno Therapeutics Inc (NASDAQ:JUNO) is poised to benefit from a rising acquisition trend.  Three weeks ago when Gilead Sciences, Inc. (NASDAQ:GILD) announced it would be acquiring smaller rival biopharma name Kite Pharma Inc (NASDAQ:KITE), traders clearly took notice.  If Gilead wanted Kite for its CAR-T cancer therapy and Novartis AG (ADR) (NYSE:NVS) recently won the first-ever FDA approval for its CAR-T based oncology drug, there had to be something to it."
BLUE,BLUE:UW,BBG004KB4FS6,Don't Make This Huge Mistake With Celgene,2017-09-17 14:35:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YH99_I8g0xc/dont-make-this-huge-mistake-with-celgene-cm846801,Several years ago I started to look seriously at investing in Celgene NASDAQ CELG stock Someone I knew told me that I probably shouldn t get too excited about the biotech I m glad I didn t listen to the person s advice Celgene is a much bigger and much more successful company
BLUE,BLUE:UW,BBG004KB4FS6,Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical,2017-09-15 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000124.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 15, 2017 / The Dow Jones Industrial Average closed at a new record high for the third consecutive session on the strength of Boeing and United Technologies, while ..."
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio Announces First Patient Treated in Expansion Cohort of CRB-401, Phase 1 Study of Anti-BCMA CAR T Therapy bb2121",2017-09-13 12:00:00 +0000,https://finance.yahoo.com/news/bluebird-bio-announces-first-patient-120000313.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that the expansion cohort of the CRB-401 Phase 1 study of bb2121, an anti-BCMA CAR T therapy, has been initiated."
BLUE,BLUE:UW,BBG004KB4FS6,5 Things You'll Want to Know From Celgene Corporation's Latest Presentation,2017-09-07 13:53:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oBJnE0iBScM/5-things-youll-want-to-know-from-celgene-corporations-latest-presentation-cm842109,It s been a busy week for biotech and healthcare conferences Drugmakers big and small have been making the rounds answering questions about their current status and future prospects Celgene Corporation NASDAQ CELG is no exception Bob Kellogg Celgene s CFO fielded questions
BLUE,BLUE:UW,BBG004KB4FS6,Here's What Lifted bluebird bio Inc. Stock 40% Higher in August,2017-09-06 20:51:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dpdO6-VWPd4/heres-what-lifted-bluebird-bio-inc-stock-40-higher-in-august-cm841904,What happened Shares of bluebird bio Inc NASDAQ BLUE a clinical stage biotech developing cell based therapies soared 40 in August according to data from S amp P Global Market Intelligence A generous takeover offer for an industry peer and an FDA approval for
BLUE,BLUE:UW,BBG004KB4FS6,Here&apos;s What Lifted bluebird bio Inc. Stock 40% Higher in August,2017-09-06 19:16:00 +0000,http://finance.yahoo.com/r/c5d8a3fc-989e-357f-9897-5f19adf9eeb0/heres-what-lifted-bluebird-bio-inc-stock-40-higher.aspx?yptr=yahoo&.tsrc=rss,Major developments in bluebird bio&apos;s neighborhood improved the biotech stock&apos;s outlook.
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy (CALD) at Child Neurology Society (CNS) 2017 Annual Meeting,2017-09-06 12:00:00 +0000,https://finance.yahoo.com/news/bluebird-bio-present-interim-clinical-120000699.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from the initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study evaluating Lenti-D™ investigational gene therapy in boys under 18 years old with cerebral adrenoleukodystrophy ..."
BLUE,BLUE:UW,BBG004KB4FS6,"IWM, KITE, GRUB, BLUE: Large Outflows Detected at ETF",2017-09-05 16:52:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f7WEDG85Gqc/iwm-kite-grub-blue-large-outflows-detected-at-etf-cm841113,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 2000 ETF Symbol IWM where we have detected an approximate 674 6 million dollar outflow that s a 1 8 decrease week over week from 269 800
BLUE,BLUE:UW,BBG004KB4FS6,"Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods",2017-09-01 18:50:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/75OeYDw6U0I/gilead-buys-kite-the-future-of-car-t-and-a-visit-to-the-new-whole-foods-cm840411,0 35 Hurricane 160 Harvey 160 and 160 North Korea 160 Tensions 2 30 160 Gilead s Acquisition of Kite Pharma What Is CAR T Therapy 4 45 Novartis CAR T Cell Therapy Receives Approval By FDA 6 50 CAR T Biotech Stocks On The Rise 10 40 Is This
BLUE,BLUE:UW,BBG004KB4FS6,5 Top Performing Stocks of the Top ETF of August,2017-09-01 15:51:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xTyVOkvZJZI/5-top-performing-stocks-of-the-top-etf-of-august-cm840241,A turbulent August ended up with positive returns for U S stocks dodging fears over North Korea tension In fact the technology sector continues to be investors hot favorite and was the clear winner last month with ARK Innovation ETF ARKK topping the list of the best performing ETF of
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio (BLUE) Looks Good: Stock Adds 11% in Session,2017-09-01 14:54:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t17DHKymBBM/bluebird-bio-blue-looks-good-stock-adds-11-in-session-cm840166,bluebird bio Inc BLUE was a big mover last session as the company saw its shares rise nearly 11 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up 40 in the
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Investor Conferences in September,2017-09-01 12:00:00 +0000,https://finance.yahoo.com/news/bluebird-bio-present-investor-conferences-120000453.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunothe"
BLUE,BLUE:UW,BBG004KB4FS6,"IPXL Reveals Oriental Stakeholder, LENS Has A Vision, STDY Is Very Shaky",2017-08-31 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ROot-VXEmZc/ipxl-reveals-oriental-stakeholder-lens-has-a-vision-stdy-is-very-shaky-20170831-01377,"IPXL Reveals Oriental Stakeholder, LENS Has A Vision, STDY Is Very Shaky"
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc Continued Its March Higher Again Today,2017-08-31 21:51:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-XGHSEdvCE8/why-bluebird-bio-inc-continued-its-march-higher-again-today-cm839982,What happened Shares of bluebird bio NASDAQ BLUE continued their seemingly unstoppable march higher this week jumping another 10 8 today as of 2 58 p m EDT after two analysts increased their price targets on the biotech All told Bluebird is up a whopping 27 for the
BLUE,BLUE:UW,BBG004KB4FS6,"ETFs with exposure to bluebird bio, Inc. : August 31, 2017",2017-08-31 21:32:20 +0000,http://finance.yahoo.com/r/2a8f40e5-3245-3daf-a476-4b5387e38df7/etfs-with-exposure-to-bluebird-bio-inc-august-31-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to bluebird bio, Inc. Here are 5 ETFs with the largest exposure to BLUE-US. Comparing the performance and risk of bluebird bio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc Continued Its March Higher Again Today,2017-08-31 19:42:00 +0000,http://finance.yahoo.com/r/2e8438cb-06ab-3f84-8b12-c170af67d224/why-bluebird-bio-inc-continued-its-march-higher-ag.aspx?yptr=yahoo&.tsrc=rss,Analyst upgrades add fuel to the fire.
BLUE,BLUE:UW,BBG004KB4FS6,"Health Care Sector Update for 08/31/2017: NVO,IPXL,STDY",2017-08-31 18:49:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5lWYIRddZCc/health-care-sector-update-for-08312017-nvoipxlstdy-cm839901,Top Health Care StocksTop Health Care Stocks JNJ 0 72 JNJ 0 72 PFE 1 61 PFE 1 61 ABT 1 10 ABT 1 10 MRK 0 50 MRK 0 50 AMGN 1 99 AMGN 1 99 Health care stocks were leading the U S markets higher today with the NYSE Health Care Index rising nearly 1 2 while shares of health
BLUE,BLUE:UW,BBG004KB4FS6,Thursday's ETF with Unusual Volume: BBH,2017-08-31 17:48:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jsRmZudX38o/thursdays-etf-with-unusual-volume-bbh-cm839844,The Biotech ETF is seeing unusually high volume in afternoon trading Thursday with over 127 000 shares traded versus three month average volume of about 31 000 Shares of BBH were up about 1 6 on the day Components of that ETF with the highest volume on Thursday were Gilead
BLUE,BLUE:UW,BBG004KB4FS6,Cramer pinpoints the trend that could lead to a surge in ...,2017-08-30 22:46:00 +0000,https://finance.yahoo.com/video/cramer-pinpoints-trend-could-lead-224600977.html?.tsrc=rss,Jim Cramer says the market's response to some recent takeovers bodes well for the acquisition market going forward.
BLUE,BLUE:UW,BBG004KB4FS6,Cramer: This trend could lead to surge in takeovers,2017-08-30 22:33:00 +0000,https://finance.yahoo.com/video/cramer-trend-could-lead-surge-223300183.html?.tsrc=rss,Jim Cramer says the market's response to some recent takeovers bodes well for the acquisition market going forward.
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc Jumped Higher Today,2017-08-30 21:50:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wJ4WvnQYe38/why-bluebird-bio-inc-jumped-higher-today-cm839403,What happened bluebird bio NASDAQ BLUE is up 10 1 at 3 40 p m EDT after Novartis NYSE NVS got its chimeric antigen receptor T cell CAR T therapy Kymriah 160 approved by the Food and Drug Administration FDA today Bluebird is developing CAR T therapies of its
BLUE,BLUE:UW,BBG004KB4FS6,Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap,2017-08-30 20:49:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pcMabnKGw6w/why-novatis-475k-car-t-cancer-treatment-is-actually-cheap-cm839366,The cancer treatment industry is celebrating a massive victory on Wednesday as Novartis NVS received approval for its innovative new lymphoblastic leukemia treatment making it the first approved CAR T therapy in the world After achieving unprecedented results in patients with this deadly
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc Jumped Higher Today,2017-08-30 20:37:00 +0000,http://finance.yahoo.com/r/5b1497ab-af91-3a50-8743-0edc5ca97146/why-bluebird-bio-inc-jumped-higher-today.aspx?yptr=yahoo&.tsrc=rss,"FDA approval of Novartis&apos; CAR-T therapy bodes well for the biotech, even if it was widely expected."
BLUE,BLUE:UW,BBG004KB4FS6,"Novartis: A New $475,000 Drug",2017-08-30 17:59:00 +0000,http://finance.yahoo.com/r/1aa47894-7cc2-3f90-9f70-36bdfc0cd64c/novartis-a-new-475-000-drug-1504115985?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The FDA issued a landmark decision today when it granted approval for Novartis’s (NVS) new leukemia Kymriah.  As Bernstein’s Tim Anderson notes: Today's approval marks a paradigm shift in how cancer patients are treated as this represents the first CAR-T approval by any company.  It shows how Novartis' R&D efforts are often focused on high science, and the company’s overall ability in R&D is (only) one of the reasons it has been one of our top picks since the start of the year.  As part of the deal, Novartis can only recognize revenue from the drug if the patient demonstrates a clinical response by the end of the first month."
BLUE,BLUE:UW,BBG004KB4FS6,"Wednesday's ETF Movers: BBH, GDXJ",2017-08-30 17:49:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UIes7EkpQpk/wednesdays-etf-movers-bbh-gdxj-cm839285,In trading on Wednesday the Biotech ETF is outperforming other ETFs up about 1 9 on the day Components of that ETF showing particular strength include shares of Bluebird Bio about 11 7 and shares of Incyte Genomics up about 6 2 on the day And underperforming other ETFs today is
BLUE,BLUE:UW,BBG004KB4FS6,Novartis Wins FDA Approval for CAR-T; So Why Is Gilead Getting a Boost?,2017-08-30 16:38:00 +0000,http://finance.yahoo.com/r/aa6d4dc3-fd9d-3ac1-a8f9-3fac57d0ebfb/novartis-wins-fda-approval-for-car-t-so-why-is-gilead-getting-a-boost-1504111101?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Swiss drug maker Novartis (NVS) won a landmark FDA approval today for the first-ever CAR-T cancer drug.  As MarketWatch reports: CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Novartis' Kymriah was approved for young people up to age 25 with a form of acute lymphoblastic leukemia.  Novartis said on Wednesday that it will work with the Centers for Medicare and Medicaid Services so medicine prices can be ""based on the clinical outcomes achieved, which would eliminate inefficiencies from the health care system."" For Kymriah, Novartis is also working with CMS ""to allow for payment only when pediatric and young adult ALL patients respond to Kymriah by the end of the first month."" Novartis did not give any specifics as to what the price range might be."
BLUE,BLUE:UW,BBG004KB4FS6,Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal,2017-08-30 12:49:12 +0000,https://finance.yahoo.com/news/juno-bluebird-hot-acquisition-targets-124912268.html?.tsrc=rss,"Gilead&apos;s (GILD) $11.8 billion deal to buy Kite Pharma KITE) has made two other leading independent CAR-T developers, Juno and Bluebird Bio hot takeover targets."
BLUE,BLUE:UW,BBG004KB4FS6,"Indecision Won't Kill You, But It Will Take Your Money",2017-08-30 00:49:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/490sbc5vNyU/indecision-wont-kill-you-but-it-will-take-your-money-cm838900,Welcome back to Mind Over Money I m Kevin Cook your field guide and story teller for the fascinating arena of Behavioral Economics This episode is all about the risk reward 160 mechanics 160 of decision making Sometimes we avoid making decisions and often we never learn from our bad ones
BLUE,BLUE:UW,BBG004KB4FS6,Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition,2017-08-29 21:50:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nk3tL-k5Ur8/juno-therapeutics-juno-continues-gains-after-gilead-kite-acquisition-cm838832,Shares of Juno Therapeutics JUNO continued to soar on Tuesday The stock has now gained nearly 40 since the announcement that fellow CAR T cancer therapy designer Kite Pharma KITE is being acquired by biotech behemoth Gilead Sciences GILD Along with Kite and Bluebird Bio BLUE Juno is
BLUE,BLUE:UW,BBG004KB4FS6,Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition,2017-08-29 19:52:07 +0000,https://finance.yahoo.com/news/juno-therapeutics-juno-continues-gains-195207952.html?.tsrc=rss,Shares of Juno Therapeutics (JUNO) continued to soar on Tuesday. The stock has now gained nearly 40% since the announcement that fellow CAR-T cancer therapy designer Kite Pharma (KITE) is being acquired by biotech behemoth Gilead Sciences (GILD).
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reaches Analyst Target Price,2017-08-29 14:48:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7yG3RqUvDTg/bluebird-bio-reaches-analyst-target-price-cm838475,In recent trading shares of bluebird bio Inc Symbol BLUE have crossed above the average analyst 12 month target price of 104 92 changing hands for 106 30 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
BLUE,BLUE:UW,BBG004KB4FS6,Holding for Harvey,2017-08-29 13:48:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gOeHODTgmrY/holding-for-harvey-cm838251,Everybody s thoughts right now are with the people of Houston and the surrounding areas due to Hurricane Harvey The storm s full impact on the market is unknown at the moment which could explain why the major indices were mostly flat on Monday Many investors want to know the extent of the
BLUE,BLUE:UW,BBG004KB4FS6,Here's What Else Gilead Sciences Gets by Buying Kite Pharma,2017-08-29 12:50:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BdXLCWNSpPw/heres-what-else-gilead-sciences-gets-by-buying-kite-pharma-cm838305,Gilead Sciences NASDAQ GILD planned 11 9 billion acquisition of Kite Pharma NASDAQ KITE nets it axi cel a CAR T therapy that s already under FDA review However axi cel isn t the only intriguing therapy in development at Kite Pharma Gilead Sciences also gets its
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : August 29, 2017",2017-08-29 12:44:22 +0000,http://finance.yahoo.com/r/d9a45448-4fd5-3dd8-a747-4b1ed05c1d12/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bullish-manner-blue-us-august-29-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for bluebird bio, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,Today's Research Reports on Trending Tickers: bluebird bio Inc. and Juno Therapeutics Inc.,2017-08-29 12:20:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-122000766.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 29, 2017 / U.S. markets were dragged down by energy and insurance shares Monday as Hurricane Harvey wreaked Havoc in Texas over the weekend. The Dow Jones Industrial ..."
BLUE,BLUE:UW,BBG004KB4FS6,ETF Topper: Booming Biotech,2017-08-28 21:39:00 +0000,http://finance.yahoo.com/r/ef112e73-f51f-3ad5-a6fb-dfe7cd60a7b8/etf-topper-booming-biotech-1503956364?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"It was a big day for biotech stocks.  Small drug makers surged in value after Gilead Sciences (GILD) announced plans to buy  Kite Pharma (KITE) for nearly $12 billion.  The deal lifted hopes for more mergers and placed a spotlight on a new class of experimental cancer drugs, all of which overshadow arguments that Gilead may have overpaid."
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today,2017-08-28 17:40:00 +0000,http://finance.yahoo.com/r/de897895-c983-3d25-a84a-15080e096c7e/why-bluebird-bio-inc-and-juno-therapeutics-inc-sho.aspx?yptr=yahoo&.tsrc=rss,The biotechs&apos; surge is related to a big move for fellow immuno-oncology drug developer Kite Pharma.
BLUE,BLUE:UW,BBG004KB4FS6,"Gilead: What the Heck is CAR-T, How Much is Too Much, and Other Kite Acquisition Questions",2017-08-28 16:49:00 +0000,http://finance.yahoo.com/r/76691ba4-5ab3-37fb-a2ba-e6344e61dfb9/gilead-what-the-heck-is-car-t-how-much-is-too-much-and-other-kite-acquisition-questions-1503938963?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Finally! If you listen closely, that sound you hear is the massive exhale by all the investors who have been holding their breath for the past year or more, waiting for Gilead Sciences (GILD) to make an acquisition.  Today, Gilead announced it would pay $180 a share -- almost $12 billion -- in cash for Kite Pharma (KITE) in what is the biggest acquisition in the drug maker’s history."
BLUE,BLUE:UW,BBG004KB4FS6,Biotech stocks surge on Gilead's Kite Pharma acquisition,2017-08-28 15:41:09 +0000,http://finance.yahoo.com/r/671493af-ede5-39f3-bda3-8da1f836c478/Story.aspx?guid=46F3FB7F-6A26-4FA2-B28D-4CFAFEA3959C&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"After news of Gilead Sciences Inc.'s about $11 billion acquisition of Kite Pharma Inc. , Juno Therapeutics Inc. shares surged 16.3%, Bluebird Bio Inc. shares surged 9.7% and Cellectis SA ADR shares surged ..."
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017",2017-08-24 15:39:17 +0000,http://finance.yahoo.com/r/bc1b514d-44b2-39e1-bc33-f0dd71a4230b/bluebird-bio-inc-blue-us-earnings-analysis-q2-2017-by-the-numbers-august-24-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis bluebird bio, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of bluebird bio, Inc. – Celgene Corporation, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals, Inc., Acceleron Pharma Inc, Sanofi Sponsored ADR, Merck & Co., Inc., Fibrocell Science, Inc., GlycoMimetics, Inc. and ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,Is This Why bluebird bio Dipped 10.5% in July?,2017-08-09 12:18:00 +0000,http://finance.yahoo.com/r/14933c1b-ed73-352e-b4a6-1b7709a49301/is-this-why-bluebird-bio-dipped-105-in-july.aspx?yptr=yahoo&.tsrc=rss,"It was a quiet month for the clinical-stage biotech, but that didn&apos;t stop its share price from dropping by double digits."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Wedbush PacGrow Healthcare Conference,2017-08-09 12:00:00 +0000,https://finance.yahoo.com/news/bluebird-bio-present-wedbush-pacgrow-120000573.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15 at 3:05 pm ET."
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. – Value Analysis (NASDAQ:BLUE) : August 7, 2017",2017-08-07 21:18:31 +0000,http://finance.yahoo.com/r/c7682d99-d808-3cbe-a737-86d718cbfc63/bluebird-bio-inc-value-analysis-nasdaqblue-august-7-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives bluebird bio, Inc. a score of 8. Our analysis is based on comparing bluebird bio, Inc. with the following peers – Celgene Corporation, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals, Inc., Acceleron Pharma Inc, Sanofi Sponsored ADR, Merck & Co., Inc., Fibrocell Science, Inc., GlycoMimetics, Inc. and Sangamo Therapeutics, ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Pauses During 2017 Data Blitz,2017-08-07 20:37:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U8of2spDxMI/bluebird-bio-pauses-during-2017-data-blitz-cm828320,Clinical stage gene therapy specialist bluebird bio NASDAQ BLUE reported 160 second quarter earnings last week which mostly just served as a reminder of its pipeline progress because revenue and earnings are essentially meaningless at this point for the biotech company For
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Pauses During 2017 Data Blitz,2017-08-07 19:20:00 +0000,http://finance.yahoo.com/r/e101ee51-ee70-3bb3-81b5-a5a7057fa0ac/bluebird-bio-inc-pauses-during-2017-data-blitz.aspx?yptr=yahoo&.tsrc=rss,"With the ASCO and EHA conferences behind it, the biotech looks to ASH to end the year with a bang."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird reports 2Q loss,2017-08-04 06:34:49 +0000,https://finance.yahoo.com/news/bluebird-reports-2q-loss-090400575.html?.tsrc=rss,"The Cambridge, Massachusetts-based company said it had a loss of $1.73 per share. The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research ..."
BLUE,BLUE:UW,BBG004KB4FS6,3 Reasons the Best Is Yet to Come for Celgene,2017-08-03 02:54:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T88UgkLb6BU/3-reasons-the-best-is-yet-to-come-for-celgene-cm826180,Celgene Corp s NASDAQ CELG second quarter revenue and sales came in nearly 50 higher than they were two short years ago yet the company doesn t appear to be anywhere near peaking A flurry of R amp D activity should provide it with a steady stream of label expansion and new
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress,2017-08-02 20:05:00 +0000,https://finance.yahoo.com/news/bluebird-bio-reports-second-quarter-200500453.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business highlights and financial results for the second quarter ended June 30, 2017."
BLUE,BLUE:UW,BBG004KB4FS6,Celgene Corporation Continues to Get It Done,2017-07-28 21:59:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qRx3HKb94VE/celgene-corporation-continues-to-get-it-done-cm823675,Celgene NASDAQ CELG continues to grow revenue 160 with its top three drugs all experiencing sales growth of at least 20 year over year in the second quarter The solid quarter allowed management to increase its 2017 earnings guidance Celgene results The raw
BLUE,BLUE:UW,BBG004KB4FS6,Biotech still has more room to run: Technician,2017-07-25 21:30:00 +0000,https://finance.yahoo.com/video/biotech-still-more-room-run-213000114.html?.tsrc=rss,"Rich Ross, Evercore ISI, discusses Amgen earnings and where else in biotech you can put your money to work. The “Fast Money” traders weigh in."
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : July 25, 2017",2017-07-25 12:19:02 +0000,http://finance.yahoo.com/r/ba96ce80-4f5d-3ae4-845a-1ef3d6f5bd24/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bullish-manner-blue-us-july-25-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for bluebird bio, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,"ETFs with exposure to bluebird bio, Inc. : July 24, 2017",2017-07-24 18:25:47 +0000,http://finance.yahoo.com/r/91609820-3aef-3232-954f-6601864cab37/etfs-with-exposure-to-bluebird-bio-inc-july-24-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to bluebird bio, Inc. Here are 5 ETFs with the largest exposure to BLUE-US. Comparing the performance and risk of bluebird bio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,"Commit To Buy bluebird bio At $50, Earn 10.4% Using Options",2017-07-21 19:06:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/68jwWlQN8Aw/commit-to-buy-bluebird-bio-at-50-earn-104-using-options-cm819516,Investors eyeing a purchase of bluebird bio Inc Symbol BLUE shares but cautious about paying the going market price of 95 30 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the January
BLUE,BLUE:UW,BBG004KB4FS6,"For Now, GE Remains a Dog of the Dow; Dimon Makes J.P. Proud - ICYMI Friday",2017-07-14 23:43:00 +0000,http://finance.yahoo.com/r/0139d9c6-c81d-34ba-8931-2db426aaeae8/for-now-ge-remains-a-dog-of-the-dow-dimon-makes-j-p-proud-icymi-friday.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Here's what you need to know now.
BLUE,BLUE:UW,BBG004KB4FS6,"ETFs with exposure to bluebird bio, Inc. : July 14, 2017",2017-07-14 17:07:33 +0000,http://finance.yahoo.com/r/f14de763-2d7d-3658-bdba-d471f0b58d52/etfs-with-exposure-to-bluebird-bio-inc-july-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to bluebird bio, Inc. Here are 5 ETFs with the largest exposure to BLUE-US. Comparing the performance and risk of bluebird bio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared,2017-07-14 00:46:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0Kn63CJBHf4/a-new-cancer-treatment-is-on-the-way-and-cancer-better-be-scared-cm815937,A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis NYSE NVS ground breaking drug for pediatric and young adult B cell acute lymphoblastic leukemia or ALL The recommendation clears the way for a formal FDA green light and it begins a
BLUE,BLUE:UW,BBG004KB4FS6,Novartis CAR-T Therapy Drug Recommended by FDA Panel,2017-07-13 22:47:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X9FqoH3jG_I/novartis-car-t-therapy-drug-recommended-by-fda-panel-cm815892,Novartis AG NVS announced that the FDA Oncologic Drugs Advisory Committee ODAC has unanimously 10 0 recommended the approval of immunocellular therapy candidate CTL019 tisagenlecleucel CTL019 an investigational chimeric antigen receptor T cell CAR T therapy is being evaluated for
BLUE,BLUE:UW,BBG004KB4FS6,"Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others",2017-07-13 13:48:00 +0000,http://finance.yahoo.com/r/ea9cdc8e-1355-328a-a984-c7171f454cff/recommendation-for-novartis-may-give-new-hope-for-some-cancer-patients.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The company received a thumbs up from an FDA advisory committee for its CAR-T therapy to treat leukemia in children and young adults.
BLUE,BLUE:UW,BBG004KB4FS6,Novartis Grabs Key FDA Panel Approval Of Experimental Cancer Drug,2017-07-12 21:08:24 +0000,http://finance.yahoo.com/r/8f5f1893-2747-3ba9-8de9-374ebf7633bc/novartis-grabs-key-fda-panel-approval-of-experimental-cancer-drug?src=A00220&yptr=yahoo&.tsrc=rss,An FDA panel voted to recommended an experimental immuno-oncology treatment from Novartis Wednesday.
BLUE,BLUE:UW,BBG004KB4FS6,A Junior Freak Out,2017-07-12 13:43:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A-Cf_3FoYZ4/a-junior-freak-out-cm814806,The July episode of the Zacks Ultimate Strategy Session is now available for viewing Tune in to this must see event when Steve Reitmeister Kevin Cook Sheraz Mian Tracey Ryniec and Brian Bolan discussed the investment landscape from most every angle Don t miss your chance to hear
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : July 11, 2017",2017-07-11 13:20:13 +0000,http://finance.yahoo.com/r/ff1eb8c9-681c-3119-aed3-033cbc09a67d/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bearish-manner-blue-us-july-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for bluebird bio, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,Billions of Dollars on the Line for Celgene With These 3 Small Biotechs,2017-07-09 12:45:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wE-hC8DNMsQ/billions-of-dollars-on-the-line-for-celgene-with-these-3-small-biotechs-cm813518,Few big drugmakers have forged as many strategic partnerships as Celgene NASDAQ CELG At last count the biotech had 47 partners and collaborators including its most recent collaboration deal with BeiGene Many investors might not realize just how much money Celgene
BLUE,BLUE:UW,BBG004KB4FS6,Billions of Dollars on the Line for Celgene With These 3 Small Biotechs,2017-07-09 11:28:00 +0000,http://finance.yahoo.com/r/d5b4c444-20a8-3696-9d0c-60e4f32908e3/billions-of-dollars-on-the-line-for-celgene-with-t.aspx?yptr=yahoo&.tsrc=rss,"Celgene&apos;s future fortunes depend heavily on Acceleron Pharma, bluebird bio, and Juno Therapeutics."
BLUE,BLUE:UW,BBG004KB4FS6,"IWM, BLUE, GPT, HLS: Large Outflows Detected at ETF",2017-07-07 16:47:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9-ltCWNd6HM/iwm-blue-gpt-hls-large-outflows-detected-at-etf-cm813090,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 2000 ETF Symbol IWM where we have detected an approximate 514 5 million dollar outflow that s a 1 4 decrease week over week from 270 600
BLUE,BLUE:UW,BBG004KB4FS6,How a Conference Caused Bluebird Bio's Shares to Rocket 33% in June,2017-07-06 03:43:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g_WlrL1UtX8/how-a-conference-caused-bluebird-bios-shares-to-rocket-33-in-june-cm812177,What happened After presenting data showing a very high response rate to a clinical stage drug in early state development 160 shares in bluebird bio NASDAQ BLUE jumped 32 6 in June according to S amp P Global Market Intelligence So what The company
BLUE,BLUE:UW,BBG004KB4FS6,How a Conference Caused Bluebird Bio&apos;s Shares to Rocket 33% in June,2017-07-06 02:31:00 +0000,http://finance.yahoo.com/r/0810ce5e-eced-3ad4-9d50-be3820722c53/how-a-conference-caused-bluebird-bios-shares-to-ro.aspx?yptr=yahoo&.tsrc=rss,A presentation at the influential American Society of Clinical Oncology in early June fueled optimism in the clinical-stage biotech company.
BLUE,BLUE:UW,BBG004KB4FS6,"Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit?",2017-06-30 20:16:38 +0000,http://finance.yahoo.com/r/9a0852a4-43d2-346c-be6c-bfa53450bf19/can-celgene-bluebird-keep-their-lead-as-rivals-champ-at-the-bit?src=A00220&yptr=yahoo&.tsrc=rss,Celgene and Bluebird stocks sustained downgrades Friday as rivals like Kite and Juno look likely to chip away at their lead in immuno-oncology drugs.
BLUE,BLUE:UW,BBG004KB4FS6,The Cure For Cancer? Look At Your Blood,2017-06-30 17:10:32 +0000,http://finance.yahoo.com/r/dc2e0f7e-738c-30ab-bf2a-12edd93714f9/drugmakers-make-science-fiction-reality-in-cancer?src=A00220&yptr=yahoo&.tsrc=rss,What once seemed sci-fi is becoming real in treating blood cancers: doctoring patients&apos; blood to kill tumors. The FDA is about to consider the first such drug.
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio: Too Much Good News?,2017-06-30 14:40:00 +0000,http://finance.yahoo.com/r/4f7a2953-e80e-3444-b70e-61b5c6bdcb41/bluebird-bio-too-much-good-news-1498833622?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Bluebird Bio (BLUE) has had a great run this year, soaring more than 73% since the start of 2017.  The drug maker emerged as a big winner from the American College of Clinical Oncology’s (ASCO) annual confab, which is part of the reasons why the stock has spiked 40% in the past month, and peaked above $120 a share along the way.  High hopes for bb2121, the experimental cancer drug Bluebird Bio is developing with Celgene (CELG), are a big ingredient in the stock’s performance."
BLUE,BLUE:UW,BBG004KB4FS6,Downsized Blue Apron Leads 5 IPOs Pricing Tonight,2017-06-28 21:10:19 +0000,http://finance.yahoo.com/r/53ffde75-eaa6-3928-8aad-16462d9afc1a/downsized-blue-apron-leads-5-ipos-pricing-tonight?src=A00220&yptr=yahoo&.tsrc=rss,Downsized Blue Apron prices tonight. But some lesser-known names also are set to debut.
BLUE,BLUE:UW,BBG004KB4FS6,2 Fastest Growing Biotech Stocks,2017-06-28 21:04:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UG9yk_buRn4/2-fastest-growing-biotech-stocks-cm809607,Even though biotech has been sky rocketing over the last five years the industry s eye popping growth spurt isn t showing any signs of slowing down In fact EvaluatePharma estimates that global prescription drug sales will rise at an astounding compound annual growth rate or CAGR
BLUE,BLUE:UW,BBG004KB4FS6,"Health Care Sector Update for 06/28/2017: BLUE,SPNC,CEMI",2017-06-28 18:42:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yY5pp2AxDc4/health-care-sector-update-for-06282017-bluespnccemi-cm809577,Top Health Care StocksTop Health Care Stocks JNJ 0 77 JNJ 0 77 PFE 0 12 PFE 0 12 ABT 0 45 ABT 0 45 MRK 0 24 MRK 0 24 AMGN 1 90 AMGN 1 90 Health care stocks remain moderately higher in recent trading with the NYSE Health Care Index posting a 0 2 increase while shares of health
BLUE,BLUE:UW,BBG004KB4FS6,ETF Winner of 1H17 and its Top 5 Stocks,2017-06-28 16:09:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uKfoyrxyoLo/etf-winner-of-1h17-and-its-top-5-stocks-cm809463,Despite the recent turmoil the technology sector continues to be investors hot favorite and is the clear winner so far That said ARK Innovation ETF ARKK has topped the list of the best performing ETFs of the first half of 2017 with impressive returns of about 45 7 read Is the Tech
BLUE,BLUE:UW,BBG004KB4FS6,InPlay from Briefing.com,2017-06-27 22:49:16 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Pricing of Public Offering of Common Stock,2017-06-27 22:29:00 +0000,https://finance.yahoo.com/news/bluebird-bio-announces-pricing-public-222900413.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of 3,810,000 shares of its common stock at a public offering price of $105.00 per share, before underwriting discounts."
BLUE,BLUE:UW,BBG004KB4FS6,Time to Take Profits in Bluebird Bio,2017-06-27 15:17:00 +0000,http://finance.yahoo.com/r/87b005fe-fb3d-3cc1-b764-73afcd2f6647/time-take-profits-bluebird-bio?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"This biotech has done well so far this year, but now it's time to lock in some gains."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Proposed Public Offering of Common Stock,2017-06-26 20:06:00 +0000,https://finance.yahoo.com/news/bluebird-bio-announces-proposed-public-200600742.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an underwritten public offering of $350 million of its common stock."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D™ Drug Product in Cerebral Adrenoleukodystrophy (CALD),2017-06-26 20:04:00 +0000,https://finance.yahoo.com/news/bluebird-bio-announces-topline-interim-200400664.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced topline interim data from the initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study evaluating Lenti-D™ investigational gene therapy in boys under 18 years old with cerebral adrenoleukodystrophy ..."
BLUE,BLUE:UW,BBG004KB4FS6,3 Reasons to Buy Celgene Stock and Never Sell,2017-06-25 16:50:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sRUM7te6lQQ/3-reasons-to-buy-celgene-stock-and-never-sell-cm807862,Celgene NASDAQ CELG stock has been in my investment portfolio since 2013 I enjoyed a couple of great years with the biotech stock performing really well Over the past couple of years however Celgene hasn t generated high returns Despite the lackluster performance since
BLUE,BLUE:UW,BBG004KB4FS6,"Why BlackBerry, Sysco, and bluebird bio Slumped Today",2017-06-23 22:50:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nTSf0PggXPA/why-blackberry-sysco-and-bluebird-bio-slumped-today-cm807675,The stock market didn t make very many big moves on Friday closing another week of extremely low volatility for major benchmarks Investors are still generally optimistic about the future for most stocks but they seem leery of making major commitments in their portfolios given key
BLUE,BLUE:UW,BBG004KB4FS6,"Why BlackBerry, Sysco, and bluebird bio Slumped Today",2017-06-23 21:01:40 +0000,http://finance.yahoo.com/r/5a916e2b-65c1-3696-a71f-668499c3c3d2/why-blackberry-sysco-and-bluebird-bio-slumped-toda.aspx?yptr=yahoo&.tsrc=rss,These stocks dropped on a quiet day on Wall Street. Find out why.
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting,2017-06-23 11:00:00 +0000,https://finance.yahoo.com/news/bluebird-bio-presents-data-hgb-110000626.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, announced new data from the ongoing HGB-205 clinical study evaluating its LentiGlobin gene therapy product candidate in patients with transfusion-dependent β-thalassemia and severe sickle cell disease ."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product at European Hematology Association (EHA) Annual Meeting,2017-06-23 11:00:00 +0000,https://finance.yahoo.com/news/bluebird-bio-announces-early-data-110000683.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, announced early interim data from the ongoing Northstar-2 Phase 3 clinical study of LentiGlobin drug product in patients with transfusion-dependent β-thalassemia and non-β0/β0 genotypes."
BLUE,BLUE:UW,BBG004KB4FS6,These Biotechs Are Leading The Sector To A 3-Month High Today,2017-06-20 16:57:03 +0000,http://finance.yahoo.com/r/bb019aaa-2994-3817-b22d-d3c911ebc678/these-biotechs-are-leading-the-sector-to-a-3-month-high-today?src=A00220&yptr=yahoo&.tsrc=rss,"Shares of cancer-focused biotechs Bluebird, Clovis and Kite popped Tuesday, leading a sectorwide boom to a three-month high."
BLUE,BLUE:UW,BBG004KB4FS6,Will These Cutting-Edge Cancer Killers Reignite The Biotech Rally?,2017-06-19 14:19:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cugF5S2JfJk/will-these-cutting-edge-cancer-killers-reignite-the-biotech-rally-cm803947,The biotech industry always a highly technical conundrum for investors might currently pose an even greater challenge 160 and offer even greater opportunities than usual Early industry innovators like Amgen AMGN Biogen BIIB and Gilead
BLUE,BLUE:UW,BBG004KB4FS6,3 Top-Performing Biotech Stocks This Week,2017-06-16 13:09:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TuZKrWahRDE/3-top-performing-biotech-stocks-this-week-cm804215,The market may be moving into the summer doldrums but some biotechnology stocks continue to put up impressive results This past week the best performing stocks in the industry included Kite Pharma NASDAQ KITE bluebird bio NASDAQ BLUE and Lexicon
BLUE,BLUE:UW,BBG004KB4FS6,3 Top-Performing Biotech Stocks This Week,2017-06-16 11:41:00 +0000,http://finance.yahoo.com/r/31ced567-a06e-39ac-922b-c09142ac8de8/3-top-performing-biotech-stocks-this-week.aspx?yptr=yahoo&.tsrc=rss,"Here&apos;s why shares of Kite Pharma, bluebird bio, and Lexicon Pharmaceuticals shot higher this past week."
BLUE,BLUE:UW,BBG004KB4FS6,Can Celgene Corporation Be a Value Stock?,2017-06-15 15:09:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pe91odb_0tg/can-celgene-corporation-be-a-value-stock-cm803809,Call me crazy but I don t think Celgene Corporation NASDAQ CELG is quite as expensive as it looks on the surface Sure the biotech stock is trading at a price to earnings multiple nearly twice that of the average stock in the benchmark S amp P 500 index but the oncology giant
BLUE,BLUE:UW,BBG004KB4FS6,The SPDR S&P Biotech (ETF) (XBI) Is on Breakout Watch,2017-06-14 12:17:48 +0000,https://finance.yahoo.com/news/spdr-p-biotech-etf-xbi-121748768.html?.tsrc=rss,"The majority of traders are laser-focused on the technology sector, so I decided to take a stroll around the Street to see what else was perking up.  Neophyte traders may not remember this, but once upon a time, biotech stocks were all the rage.  The biotech ETF suffered a 50% haircut and has been clawing its way back ever since."
BLUE,BLUE:UW,BBG004KB4FS6,"Excitement from ASCO: TG Thereapeutics, Loxo Oncology, and Bluebird Bio",2017-06-13 15:30:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n_a-kdGyzFc/excitement-from-asco-tg-thereapeutics-loxo-oncology-and-bluebird-bio-cm802676,Clinical stage biotech companies put their best foot forward at the annual American Society of Clinical Oncology meeting earlier this week but while many companies released data it was presentations from bluebird bio NASDAQ BLUE TG Therapeutics NASDAQ TGTX and
BLUE,BLUE:UW,BBG004KB4FS6,"Excitement from ASCO: TG Thereapeutics, Loxo Oncology, and Bluebird Bio",2017-06-13 13:29:00 +0000,http://finance.yahoo.com/r/780dd542-afa9-3c18-8f22-243958fa3931/industry-focus-healthcare-06-07-2017.aspx?yptr=yahoo&.tsrc=rss,"After presentations at the annual American Society of Clinical Oncology conference this week sent shares higher, investors in bluebird bio, TG Therapeutics, and Loxo Oncology are cheering."
BLUE,BLUE:UW,BBG004KB4FS6,What Investors Missed in the Market Last Week,2017-06-11 19:26:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LWKOYEgMo0A/what-investors-missed-in-the-market-last-week-cm801712,Despite the Dow Jones Industrial Average and S amp P 500 hitting intraday highs Friday the markets took an abrupt downturn thanks in large part to the technology sector which ended hopes of the S amp P 500 logging a weekly gain However the Dow managed to post a modest 0
BLUE,BLUE:UW,BBG004KB4FS6,What Investors Missed in the Market Last Week,2017-06-11 17:33:00 +0000,http://finance.yahoo.com/r/06f38945-67ba-3259-a8a0-e52dc665d08c/what-investors-missed-in-the-market-last-week-4.aspx?yptr=yahoo&.tsrc=rss,"Snap was hit with a flurry of downgrades last week, retailers continue to struggle, and one company recorded promising cancer-treatment results."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Appoints Two New Directors to its Board,2017-06-08 20:46:00 +0000,http://finance.yahoo.com/r/9bd547a1-11af-33f6-99e1-71eb6771fef7/bluebird-bio-appoints-two-new-directors-to-its-board.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"bluebird bio appointed John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to its Board of Directors."
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio Appoints John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to Board of Directors",2017-06-08 20:05:00 +0000,https://finance.yahoo.com/news/bluebird-bio-appoints-john-o-200500359.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has appointed John O."
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. – Value Analysis (NASDAQ:BLUE) : June 8, 2017",2017-06-08 18:07:07 +0000,http://finance.yahoo.com/r/15da8048-2fe3-3aa2-be57-15e10a967269/bluebird-bio-inc-value-analysis-nasdaqblue-june-8-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives bluebird bio, Inc. a score of 8. Our analysis is based on comparing bluebird bio, Inc. with the following peers – Celgene Corporation, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals, Inc., Acceleron Pharma Inc, Sanofi Sponsored ADR, Merck & Co., Inc., Fibrocell Science, Inc., GlycoMimetics, Inc. and Sangamo Therapeutics, ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,J.P. Morgan analyst crowns Bluebird Bio the ‘clear winner’ at major cancer conference,2017-06-08 11:46:45 +0000,http://finance.yahoo.com/r/81d158df-361b-356b-904f-14c9b97957f5/Story.aspx?guid=165A2042-4AD1-11E7-8783-F3646137DD9B&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Results for an early-stage clinical trial met already-high expectations.
BLUE,BLUE:UW,BBG004KB4FS6,"Gainers & Losers Of June 7: NH, CRUS, PTCT, ANAB, ACRX...",2017-06-08 00:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9ktmTE5eBQs/gainers--losers-of-june-7-nh-crus-ptct-anab-acrx-20170608-00005,"Gainers & Losers Of June 7: NH, CRUS, PTCT, ANAB, ACRX..."
BLUE,BLUE:UW,BBG004KB4FS6,"Why Hawaiian Holdings, MBIA, and bluebird bio Jumped Today",2017-06-07 22:27:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pT4XXJNVpuc/why-hawaiian-holdings-mbia-and-bluebird-bio-jumped-today-cm800304,The stock market regained some ground on Wednesday as major benchmarks eased higher to make up for losses earlier in the week Market participants kept their eyes on Washington where written remarks from former FBI Director James Comey ahead of his hearing tomorrow drew plenty
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc. Flew Higher Again Today,2017-06-07 22:27:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QbPtvuETDgY/why-bluebird-bio-inc-flew-higher-again-today-cm800299,What happened bluebird bio NASDAQ BLUE closed up 11 2 on Wednesday continuing its three day run following the presentation at the American Society of Clinical Oncology ASCO 160 meeting on Monday Positive comments from J P Morgan biotech analyst Cory Kasimoc could
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc. Flew Higher Again Today,2017-06-07 20:53:00 +0000,http://finance.yahoo.com/r/cd68c6fc-ab95-3d8d-8f8d-dbb7fb401adb/why-bluebird-bio-inc-flew-higher-again-today.aspx?yptr=yahoo&.tsrc=rss,The biotech&apos;s post-ASCO run continues.
BLUE,BLUE:UW,BBG004KB4FS6,"Why Hawaiian Holdings, MBIA, and bluebird bio Jumped Today",2017-06-07 20:32:00 +0000,http://finance.yahoo.com/r/c71bb82d-9ac9-3cf9-b712-ffd3ea63a05f/why-hawaiian-holdings-mbia-and-bluebird-bio-jumped.aspx?yptr=yahoo&.tsrc=rss,"These stocks climbed, helping to pull up the overall market. Find out why."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reaches Analyst Target Price,2017-06-07 15:20:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JCQyzEucHuM/bluebird-bio-reaches-analyst-target-price-cm799960,In recent trading shares of bluebird bio Inc Symbol BLUE have crossed above the average analyst 12 month target price of 93 32 changing hands for 98 20 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
BLUE,BLUE:UW,BBG004KB4FS6,3 Promising Stocks to Buy Now,2017-06-07 14:19:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-tSRyIZHGlA/3-promising-stocks-to-buy-now-cm799922,Shopify NYSE SHOP Lumentum NASDAQ LITE 160 and bluebird bio NASDAQ BLUE are three of the most promising stocks on my watch list to buy right now These three companies have very different businesses but each one has catalysts coming that could fuel future
BLUE,BLUE:UW,BBG004KB4FS6,3 Promising Stocks to Buy Now,2017-06-07 12:22:00 +0000,http://finance.yahoo.com/r/1320692b-4a10-3dda-9a7c-46f82d06eed8/3-promising-stocks-to-buy-now.aspx?yptr=yahoo&.tsrc=rss,"Shopify, Lumentum, and bluebird bio could be on the cusp of becoming much bigger companies, according to this Motley Fool contributor."
BLUE,BLUE:UW,BBG004KB4FS6,Blood and bone marrow therapies grab spotlight at world's top cancer meeting,2017-06-07 11:00:00 +0000,https://finance.yahoo.com/news/blood-bone-marrow-therapies-grab-110000184.html?.tsrc=rss,"Promising new data on blood and  bone marrow cancer therapies that re-engineer immune system  cells are convincing more doctors of the validity of the  approach, according to Reuters interviews at the world's biggest  annual oncology meeting.  Chimeric antigen receptor T-cell, or CAR-T, therapies  extract immune system T-cells from an individual patient, alter  their DNA to better spot and kill cancer cells, and infuse them  back into the same patient.  Investors had been closely watching the fortunes of CAR-T  developers, including Kite Pharma Inc and Bluebird Bio  Inc. This week, the therapies took center stage at the  American Society of Clinical Oncology (ASCO) annual meeting,  with new results on their use for multiple myeloma patients."
BLUE,BLUE:UW,BBG004KB4FS6,"Gainers & Losers Of June 6: VTL, EGLT, AMRI, AGLE, CRVS...",2017-06-06 21:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K3VHQ4BgSNM/gainers--losers-of-june-6-vtl-eglt-amri-agle-crvs-20170606-01380,"Gainers & Losers Of June 6: VTL, EGLT, AMRI, AGLE, CRVS..."
BLUE,BLUE:UW,BBG004KB4FS6,This Small Biotech Soared On Its Celgene-Partnered Trial,2017-06-06 20:58:35 +0000,http://finance.yahoo.com/r/907770dc-c082-3cc0-9d9f-5a249899bed1/this-small-biotech-is-breaking-out-on-its-celgene-partnered-trial?src=A00220&yptr=yahoo&.tsrc=rss,"Bluebird Bio stock rocketed to a 20-month high Tuesday, busting into a buy zone, on strong data presented Monday in a cancer trial with Celgene."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Inc (BLUE) Leads the Way in the Next Wave of CAR-Ts,2017-06-06 19:58:33 +0000,https://finance.yahoo.com/news/bluebird-bio-inc-blue-leads-195833136.html?.tsrc=rss,"Cowen analyst Eric Schmidt is out today with a research note on shares of bluebird bio Inc (NASDAQ:BLUE), following updated data from the company's Phase 1 study with bb2121 in relapsed/refractory multiple myeloma (r/r MM). At the 2017 American Society of Clinical Oncology (ASCO) meeting, bluebird reported updated followup data with 100% overall response rates in patients treated with doses higher than 50x106 cells."
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc Flew Higher Today,2017-06-06 19:18:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UNQVOJZfTv0/why-bluebird-bio-inc-flew-higher-today-cm799599,What happened bluebird bio NASDAQ BLUE is up 11 at 12 34 p m EDT Tuesday after presenting solid early stage data for its cancer treatment codenamed bb2121 at the American Society of Clinical Oncology 160 meeting on Monday Theoretically the data should have been priced
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc Flew Higher Today,2017-06-06 17:40:00 +0000,http://finance.yahoo.com/r/69e9e0fa-6307-381b-9bef-9556ceb46af0/why-bluebird-bio-inc-flew-higher-today.aspx?yptr=yahoo&.tsrc=rss,Solid early-stage data for its CAR-T treatment bb2121 has investors looking up.
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio (BLUE) Looks Good: Stock Adds 8.5% in Session,2017-06-06 14:04:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nfrLms5c3-M/bluebird-bio-blue-looks-good-stock-adds-85-in-session-cm799358,bluebird bio Inc BLUE was a big mover last session as the company saw its shares rise almost 9 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above
BLUE,BLUE:UW,BBG004KB4FS6,"Bluebird Bio Is Liked by Analysts, Cognizant Isn't",2017-06-06 12:55:00 +0000,https://finance.yahoo.com/news/bluebird-bio-liked-analysts-cognizant-125500436.html?.tsrc=rss,"Here are Tuesday's top research calls, including upgrades for Bluebird Bio and Tenet Healthcare, a downgrade for Cognizant and new coverage of Hormel."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio (BLUE) Looks Good: Stock Adds 8.5% in Session,2017-06-06 12:35:12 +0000,https://finance.yahoo.com/news/bluebird-bio-blue-looks-good-123512104.html?.tsrc=rss,bluebird bio saw its shares rise almost 9% on the day on the back of the company&apos;s recently released updated results from an ongoing early-stage clinical trial in relapsed/refractory multiple myeloma..
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : June 6, 2017",2017-06-06 12:04:32 +0000,http://finance.yahoo.com/r/8a85b30c-1c73-3afc-bfa8-fc25e4494a3b/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bullish-manner-blue-us-june-6-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for bluebird bio, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,"Gainers & Losers Of June 5: LOXO, CLSN, RDUS, GLYC, JUNO...",2017-06-05 22:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nkjIXwy7ShE/gainers--losers-of-june-5-loxo-clsn-rdus-glyc-juno-20170605-01326,"Gainers & Losers Of June 5: LOXO, CLSN, RDUS, GLYC, JUNO..."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio shares pop on what CEO calls ‘very exciting’ cancer news,2017-06-05 21:28:34 +0000,https://finance.yahoo.com/news/bluebird-bio-shares-pop-ceo-212834631.html?.tsrc=rss,Bluebird Bio CEO Nick Leschly said the multiple myeloma patients in a study have had an &quot;incredible response rate.&quot;
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio shares pop on what CEO calls ‘very exciting’ cancer news,2017-06-05 21:28:34 +0000,http://finance.yahoo.com/r/fb8bed38-4686-3bf5-9b46-3f6a9fe24905/104511351?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104511351&yptr=yahoo&.tsrc=rss,"Bluebird Bio CEO Nick Leschly said the multiple myeloma patients in a study have had an ""incredible response rate."""
BLUE,BLUE:UW,BBG004KB4FS6,"Notable Monday Option Activity: HAIN, URBN, BLUE",2017-06-05 17:00:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r_3XpQK3uAc/notable-monday-option-activity-hain-urbn-blue-cm798791,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Hain Celestial Group Inc Symbol HAIN where a total of 6 715 contracts have traded so far representing approximately 671 500 underlying shares That amounts to about 48 9 of HAIN
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio stock rises 5% on positive data from ongoing early-stage clinical trial,2017-06-05 13:34:37 +0000,https://finance.yahoo.com/news/bluebird-bio-stock-rises-5-133437300.html?.tsrc=rss,Bluebird Bio Inc. shares rose as much as 5% in morning trade Monday after the company released updated results from an ongoing early-stage clinical trial in relapsed/refractory multiple myeloma. Relapsed ...
BLUE,BLUE:UW,BBG004KB4FS6,"Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free",2017-06-05 11:30:00 +0000,http://finance.yahoo.com/r/70325457-ebf0-334c-95a4-e2726b2b6edb/bluebird-celgene-car-t-keeps-multiple-myeloma-patients-relapse-free.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,100% response rate with zero relapses are the latest update from Bluebird's BB2121 study in multiple myeloma patients.
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting,2017-06-05 11:30:00 +0000,https://finance.yahoo.com/news/bluebird-bio-celgene-corporation-announce-113000157.html?.tsrc=rss,"bluebird bio, Inc. , and Celgene Corporation today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell therapy, in 18 patients with relapsed/refractory multiple myeloma will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Inc. (BLUE) Is Climbing On Study Results,2017-06-05 09:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tBj4t21jnlY/bluebird-bio-inc-blue-is-climbing-on-study-results-20170605-00729,Bluebird Bio Inc. (BLUE) Is Climbing On Study Results
BLUE,BLUE:UW,BBG004KB4FS6,Stocks to watch during ASCO,2017-06-02 16:49:00 +0000,https://finance.yahoo.com/video/stocks-watch-during-asco-164900354.html?.tsrc=rss,"CNBC's Meg Tirrell reports on what stocks to watch during ASCO, the biggest cancer research conference in Chicago. The “Fast Money Halftime Report” traders weigh in."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio stock jumps 7% after Maxim Group upgrades to buy,2017-06-02 12:15:30 +0000,http://finance.yahoo.com/r/5ee3949d-5bfe-3e3a-bf50-d3c02cdd6499/Story.aspx?guid=46254AE9-5AF6-4939-B73A-6C3613956D5C&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Bluebird Bio Inc. shares jumped 7.3% in premarket trade Friday after the company was upgraded to buy from hold at Maxim Group, with a price target of $100, above the company's $79.20 share price as of ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Two Investor Conferences in June,2017-06-01 12:00:00 +0000,https://finance.yahoo.com/news/bluebird-bio-present-two-investor-120000124.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunothe"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : May 23, 2017",2017-05-23 12:06:18 +0000,http://finance.yahoo.com/r/0118bafb-0745-3c75-a343-80a026508638/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bearish-manner-blue-us-may-23-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for bluebird bio, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio Announces Collaboration with Duke University’s Robert J. Margolis, MD, Center for Health Policy on Value-Based Payment Framework for Gene Therapy",2017-05-23 12:00:00 +0000,https://finance.yahoo.com/news/bluebird-bio-announces-collaboration-duke-120000775.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that it will participate in a consortium led by Duke University’s Robert J."
BLUE,BLUE:UW,BBG004KB4FS6,"ETFs with exposure to bluebird bio, Inc. : May 22, 2017",2017-05-22 17:24:30 +0000,http://finance.yahoo.com/r/4541b0a5-8f0e-3c6f-a182-94739f87e8e9/etfs-with-exposure-to-bluebird-bio-inc-may-22-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to bluebird bio, Inc. Here are 5 ETFs with the largest exposure to BLUE-US. Comparing the performance and risk of bluebird bio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting,2017-05-18 10:09:00 +0000,https://finance.yahoo.com/news/bluebird-bio-present-data-lentiglobintm-100900483.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that data from ongoing clinical studies of LentiGlobin drug product in transfusion-dependent β-thalassemia and severe sickle cell disease will be highlighted in oral and poster presentations at the 22nd Congress ..."
BLUE,BLUE:UW,BBG004KB4FS6,"Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting",2017-05-17 21:10:00 +0000,http://finance.yahoo.com/r/5de8fd0e-5a6d-3c8b-8476-507373b08b4a/bluebird-kite-and-juno-delivering-car-t-cancer-study-updates-to-asco-17-meeting.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting,2017-05-17 21:00:00 +0000,https://finance.yahoo.com/news/bluebird-bio-present-updated-clinical-210000589.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that updated interim data from its study of bb2121, the company’s anti-BCMA CAR T cell therapy will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois."
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : May 12, 2017",2017-05-12 12:55:53 +0000,http://finance.yahoo.com/r/9bf6c621-160d-3eec-b91e-70706532473f/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bearish-manner-blue-us-may-12-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for bluebird bio, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,"ETFs with exposure to bluebird bio, Inc. : May 8, 2017",2017-05-08 20:13:18 +0000,http://finance.yahoo.com/r/2901725e-5e40-3aa2-923a-f4d87e702503/etfs-with-exposure-to-bluebird-bio-inc-may-8-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to bluebird bio, Inc. Here are 5 ETFs with the largest exposure to BLUE-US. Comparing the performance and risk of bluebird bio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio Updates, Investors Wait",2017-05-05 22:25:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0WqSWGtQcDk/bluebird-bio-updates-investors-wait-cm785303,As per its common habit bluebird bio NASDAQ BLUE did not announce the timing of it first quarter earnings report ahead of schedule nor did the biotech s management hold a conference call to discuss it after they released it Nevertheless the release offers an opportunity
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio Updates, Investors Wait",2017-05-05 21:03:00 +0000,http://finance.yahoo.com/r/d9b0f782-2b10-3860-a79d-8de5f41fba0f/bluebird-bio-inc-updates-investors-wait.aspx?yptr=yahoo&.tsrc=rss,Earnings releases aren&apos;t particularly exciting when a biotech doesn&apos;t have any products on the market yet.
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017",2017-05-05 14:32:50 +0000,http://finance.yahoo.com/r/2788e546-1e97-3a3a-8e89-74a9d5590358/bluebird-bio-inc-blue-us-earnings-analysis-q1-2017-by-the-numbers-may-5-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis bluebird bio, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of bluebird bio, Inc. – Celgene Corporation and Merck & Co., Inc. (CELG-US and MRK-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 6.83 ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,Fed: No Worries About Q1 Weakness,2017-05-04 14:13:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4ttCHRLBEJg/fed-no-worries-about-q1-weakness-cm783897,The Fed announcement on Wednesday was every bit the non event that the market thought it would be The Committee held interest rates steady and said recent economic weakness is transitory Therefore it remains on course for two more rate hikes this year With that bit of business out of the
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird reports 1Q loss,2017-05-03 21:30:51 +0000,http://finance.yahoo.com/news/bluebird-reports-1q-loss-213051248.html?.tsrc=rss,"The Cambridge, Massachusetts-based company said it had a loss of $1.68 per share. The results surpassed Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress,2017-05-03 20:05:00 +0000,http://finance.yahoo.com/news/bluebird-bio-reports-first-quarter-200500829.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business highlights and financial results for the first quarter ended March 31, 2017."
BLUE,BLUE:UW,BBG004KB4FS6,"Cambridge's bluebird bio licenses delivery tech to Novartis, GSK",2017-05-02 15:10:09 +0000,http://finance.yahoo.com/r/dc8397be-ec6b-343a-b367-1cca935128d2/cambridges-bluebird-bio-licenses-delivery-tech-to.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Cambridge-based bluebird bio said Tuesday that Novartis and GlaxoSmithKline will pay undisclosed sums to license its technology for delivering genetic material into cells.  Bluebird bio (BLUE) announced that it's selling the non-exclusive rights to the patents covering the technology, called lentiviral vectors, to Novartis (NVS) for use in developing cancer treatments and to GSK (GSK) for drugs targeting rare genetic diseases."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Enters Lentiviral Vector Patent License Agreement with GlaxoSmithKline for Commercialization of Gene Therapies,2017-05-02 12:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-enters-lentiviral-vector-120000421.html?.tsrc=rss,"bluebird bio, Inc. today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with GlaxoSmithKline Intellectual Property Development Limited ."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies,2017-05-02 12:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-licenses-lentiviral-vector-120000653.html?.tsrc=rss,"bluebird bio, Inc. today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma AG."
BLUE,BLUE:UW,BBG004KB4FS6,"Better Buy: Ionis Pharmaceuticals, Inc. vs. bluebird bio",2017-04-27 17:31:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cylZBQVTC6o/better-buy-ionis-pharmaceuticals-inc-vs-bluebird-bio-cm780433,The most promising biotechs have productive platforms and are pioneering new approaches to treating conditions difficult to address with conventional therapies Two that fit that bill are Ionis Pharmaceuticals NASDAQ IONS and bluebird bio NASDAQ BLUE Which one represents
BLUE,BLUE:UW,BBG004KB4FS6,"Better Buy: Ionis Pharmaceuticals, Inc. vs. bluebird bio",2017-04-27 15:46:00 +0000,http://finance.yahoo.com/r/23842e6e-a993-338f-972d-bba12d3670af/better-buy-ionis-pharmaceuticals-inc-vs-bluebird-b.aspx?yptr=yahoo&.tsrc=rss,Which of these two pioneering biotech companies are the best place for new money today?
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Upcoming Investor Conferences,2017-04-26 20:30:00 +0000,http://finance.yahoo.com/news/bluebird-bio-present-upcoming-investor-203000880.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunothe"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : April 26, 2017",2017-04-26 12:41:21 +0000,http://finance.yahoo.com/r/d0bf519d-f7ce-357a-9a5b-021d9ea9731c/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bullish-manner-blue-us-april-26-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for bluebird bio, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,"3 Things You Didn't Know About bluebird bio, Inc.",2017-04-25 22:06:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uzyvWr535SY/3-things-you-didnt-know-about-bluebird-bio-inc-cm779094,Gene therapy leader bluebird bio NASDAQ BLUE has made waves in the CAR T space although it s still trailing the CAR T front runners But here are three things you might not know about the promising biotech 1 The company was originally named Genetix Pharmaceuticals
BLUE,BLUE:UW,BBG004KB4FS6,"3 Things You Didn&apos;t Know About bluebird bio, Inc.",2017-04-25 20:20:00 +0000,http://finance.yahoo.com/r/02a040a5-a8ac-3c5b-8575-964c85caa98d/3-things-you-didnt-know-about-bluebird-bio-inc.aspx?yptr=yahoo&.tsrc=rss,Going beyond LentiGlobin and CAR-T.
BLUE,BLUE:UW,BBG004KB4FS6,"Commit To Buy bluebird bio At $60, Earn 19.5% Using Options",2017-04-20 17:05:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jj9dtgiCJ1A/commit-to-buy-bluebird-bio-at-60-earn-195-using-options-cm776528,Investors eyeing a purchase of bluebird bio Inc Symbol BLUE stock but tentative about paying the going market price of 80 30 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the January
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. – Value Analysis (NASDAQ:BLUE) : April 17, 2017",2017-04-17 17:23:11 +0000,http://finance.yahoo.com/r/b9d6f168-02b5-3543-880f-eaad48a51e3a/bluebird-bio-inc-value-analysis-nasdaqblue-april-17-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives bluebird bio, Inc. a score of 8. Our analysis is based on comparing bluebird bio, Inc. with the following peers – Celgene Corporation, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals, Inc., Acceleron Pharma Inc, Sanofi Sponsored ADR, Merck & Co., Inc., Fibrocell Science, Inc., GlycoMimetics, Inc. and Sangamo Therapeutics, ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : April 13, 2017",2017-04-13 12:15:25 +0000,http://finance.yahoo.com/r/e209ce2b-d5e0-39a2-a421-fc3128e88038/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bearish-manner-blue-us-april-13-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for bluebird bio, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,BLUE Crosses Above Average Analyst Target,2017-04-10 14:54:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iV6ApcKbLRc/blue-crosses-above-average-analyst-target-cm772066,In recent trading shares of bluebird bio Inc Symbol BLUE have crossed above the average analyst 12 month target price of 85 58 changing hands for 87 40 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
BLUE,BLUE:UW,BBG004KB4FS6,The First CAR-T Drugs Have Left the Gate,2017-04-06 21:55:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JxFpn9xMdn4/the-first-car-t-drugs-have-left-the-gate-cm771072,For all the talk about biotechs being nimble it s a big pharma that looks like it ll be the first company to launch a chimeric antigen receptor T cell CAR T product Novartis NYSE NVS announced last week that the Food and Drug Administration accepted its application to
BLUE,BLUE:UW,BBG004KB4FS6,European Markets Finished Mostly Lower In Lackluster Trade,2017-03-24 12:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HL2ktYEOlBI/european-markets-finished-mostly-lower-in-lackluster-trade-20170324-00588,European Markets Finished Mostly Lower In Lackluster Trade
BLUE,BLUE:UW,BBG004KB4FS6,European Shares Retreat On Trump Policy Uncertainty,2017-03-24 06:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wJ1rm2gG6D0/european-shares-retreat-on-trump-policy-uncertainty-20170324-00138,European Shares Retreat On Trump Policy Uncertainty
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Appoints New Senior Manufacturing and Corporate Development Executives,2017-03-20 12:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-appoints-senior-manufacturing-120000717.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that Derek Adams, Ph.D."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Appoints New Senior Manufacturing and Corporate Development Executives,2017-03-20 12:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-appoints-senior-manufacturing-120000717.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that Derek Adams, Ph.D."
BLUE,BLUE:UW,BBG004KB4FS6,3 tech and biotech stocks with momentum,2017-03-16 12:52:11 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=DBCDD42A-09BF-11E7-9108-9B9BDCA7849D&siteid=yhoof2,3 tech and biotech stocks with momentum
BLUE,BLUE:UW,BBG004KB4FS6,3 tech and biotech stocks with momentum,2017-03-16 12:52:11 +0000,http://finance.yahoo.com/r/3457ed09-6352-3ce1-8f39-eab65458c116/Story.aspx?guid=DBCDD42A-09BF-11E7-9108-9B9BDCA7849D&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Harry Boxer is tracking bluebird bio, Clovis Oncology and Boingo Wireless."
BLUE,BLUE:UW,BBG004KB4FS6,BLUE Crosses Above Average Analyst Target,2017-03-10 15:13:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iAXb6Xcq454/blue-crosses-above-average-analyst-target-cm759254,In recent trading shares of bluebird bio Inc Symbol BLUE have crossed above the average analyst 12 month target price of 84 83 changing hands for 86 80 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
BLUE,BLUE:UW,BBG004KB4FS6,Better Buy: Bellicum Pharmaceuticals Inc. vs. bluebird bio Inc.,2017-03-06 16:15:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UgYQOoRBk64/better-buy-bellicum-pharmaceuticals-inc-vs-bluebird-bio-inc-cm756585,Bellicum Pharmaceuticals Inc NASDAQ BLCM and bluebird bio Inc NASDAQ BLUE occupy an interesting corner of the biotech industry Both clinical stage biotechs are developing cellular therapies for the treatment of blood disorders and cancer Neither has an approved product
BLUE,BLUE:UW,BBG004KB4FS6,Better Buy: Bellicum Pharmaceuticals Inc. vs. bluebird bio Inc.,2017-03-06 14:42:00 +0000,http://finance.yahoo.com/r/64d8721e-e01e-34cf-a5d7-e0c57bdc357f/better-buy-bellicum-pharmaceuticals-inc-vs-bluebir.aspx?yptr=yahoo&.tsrc=rss,"Several of the most interesting drugs in development belong to Bellicum and bluebird bio, but which is the better stock pick right now?"
BLUE,BLUE:UW,BBG004KB4FS6,Better Buy: Bellicum Pharmaceuticals Inc. vs. bluebird bio Inc.,2017-03-06 14:42:00 +0000,http://www.fool.com/investing/2017/03/06/better-buy-bellicum-pharmaceuticals-inc-vs-bluebir.aspx,Better Buy: Bellicum Pharmaceuticals Inc. vs. bluebird bio Inc.
BLUE,BLUE:UW,BBG004KB4FS6,"Four biotech stocks surging on optimism about drug trials, product launches",2017-03-03 14:09:44 +0000,http://finance.yahoo.com/r/6afbc72a-eb16-3e86-a3ee-a58bf2516d97/Story.aspx?guid=9F140324-FF74-11E6-AB63-2E992CB9A6D8&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Harry Boxer highlights bluebird bio, Amicus Therapeutics, Kite Pharma and NeuroDerm."
BLUE,BLUE:UW,BBG004KB4FS6,"Four biotech stocks surging on optimism about drug trials, product launches",2017-03-03 14:09:44 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=9F140324-FF74-11E6-AB63-2E992CB9A6D8&siteid=yhoof2,"Four biotech stocks surging on optimism about drug trials, product launches"
BLUE,BLUE:UW,BBG004KB4FS6,Biotechs Breaking Out On Drug Development News,2017-03-02 20:34:00 +0000,http://www.forbes.com/sites/greatspeculations/2017/03/02/biotechs-breaking-out-on-drug-development-news/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Biotechs Breaking Out On Drug Development News
BLUE,BLUE:UW,BBG004KB4FS6,4 Biotech Stocks Breaking Out On Positive Drug Developments,2017-03-02 18:47:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hwjOnrl12Hc/4-biotech-stocks-breaking-out-on-positive-drug-developments-cm755572,"Here are four biotech stocks breaking out on positive developments related to their drugs.  bluebird bio, Inc. ( BLUE ) has popped about 20 points in a week to Wednesday's close of $92.80.  On Wednesday alone, it rose $5.15 on over 1 million shares traded, closing just a dime off the high. The company announced"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine,2017-03-01 22:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-announces-publication-case-220000604.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the publication in the New England Journal of Medicine of a case study on Patient 1204, the first patient with severe sickle cell disease to be treated with gene therapy."
BLUE,BLUE:UW,BBG004KB4FS6,5:00 pm Bluebirdbio announces publication of case study on first patient with severe sickle cell disease treated with gene therapy in NEJM,2017-03-01 22:00:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#blue,5:00 pm Bluebirdbio announces publication of case study on first patient with severe sickle cell disease treated with gene therapy in NEJM
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine,2017-03-01 22:00:00 +0000,http://uk.finance.yahoo.com/news/bluebird-bio-announces-publication-case-220000651.html,bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine
BLUE,BLUE:UW,BBG004KB4FS6,"Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals",2017-02-28 20:51:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DhyPAbFdy0U/better-buy-bluebird-bio-inc-vs-alnylam-pharmaceuticals-cm754355,In this edition of our ongoing Better Buy series we ve got two biotechs trading well off their highs bluebird bio NASDAQ BLUE peaked in the middle of 2015 when it appeared that the company s gene therapy was able to cure sickle cell anemia patients Subsequent patients didn
BLUE,BLUE:UW,BBG004KB4FS6,"Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals",2017-02-28 18:40:00 +0000,http://www.fool.com/investing/2017/02/28/better-buy-bluebird-bio-inc-vs-alnylam-pharmaceuti.aspx,"Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals"
BLUE,BLUE:UW,BBG004KB4FS6,"Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals",2017-02-28 18:40:00 +0000,http://finance.yahoo.com/r/a1265d34-2d26-39a4-9f79-dc8383c7f7aa/better-buy-bluebird-bio-inc-vs-alnylam-pharmaceuti.aspx?yptr=yahoo&.tsrc=rss,A battle of knocked-down platform biotechs.
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Financials",2017-02-28 18:04:09 +0000,http://finance.yahoo.com/q/is?s=blue,"BLUEBIRD BIO, INC. Financials"
BLUE,BLUE:UW,BBG004KB4FS6,Kite Pharma's cancer drug clears main goal in study,2017-02-28 14:18:06 +0000,http://finance.yahoo.com/news/kite-pharmas-cancer-drug-clears-133617247.html?.tsrc=rss,"Kite Pharma Inc said on Tuesday  its experimental CAR T-cell therapy, which helps the immune  system fight cancer, was highly effective in treating aggressive  non-Hodgkin lymphoma, meeting the main goal of a key study.  CAR T-cell drugs are made by genetically altering a  patients' own T-cells to add a component of antibodies that  makes them better able to spot and kill cancer cells.  Non-Hodgkin Lymphoma occurs when the body produces too many  abnormal lymphocytes, a type of white blood cell."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Two Investor Conferences in March,2017-02-28 13:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-present-two-investor-130000846.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunothe"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Two Investor Conferences in March,2017-02-28 13:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-present-two-investor-130000846.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunothe"
BLUE,BLUE:UW,BBG004KB4FS6,Bluebirdbio downgraded by Maxim Group,2017-02-27 18:42:10 +0000,http://finance.yahoo.com/q/ud?s=BLUE,Bluebirdbio downgraded by Maxim Group
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: 2016 By the Numbers : February 27, 2017",2017-02-27 18:33:41 +0000,http://finance.yahoo.com/r/c540a35a-15d5-397b-af67-456b3571cd13/bluebird-bio-inc-blue-us-earnings-analysis-2016-by-the-numbers-february-27-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis bluebird bio, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of bluebird bio, Inc. – Celgene Corporation, BioMarin Pharmaceutical Inc., Sanofi Sponsored ADR and Merck & Co., Inc. (CELG-US, BMRN-US, SNY-US and MRK-US) that have also reported for this ... Read more    
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: 2016 By the Numbers : February 27, 2017",2017-02-27 18:33:41 +0000,http://www.capitalcube.com/blog/index.php/bluebird-bio-inc-blue-us-earnings-analysis-2016-by-the-numbers-february-27-2017/,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: 2016 By the Numbers : February 27, 2017"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q4, 2016 By the Numbers : February 24, 2017",2017-02-24 15:28:56 +0000,http://finance.yahoo.com/r/712c62e6-87b6-301c-ba61-f138bf175547/bluebird-bio-inc-blue-us-earnings-analysis-q4-2016-by-the-numbers-february-24-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis bluebird bio, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of bluebird bio, Inc. – Celgene Corporation, Sanofi Sponsored ADR and Merck & Co., Inc. (CELG-US, SNY-US and MRK-US) that have also reported for this period. Highlights Summary numbers: ... Read more    
<b>(Read more...)</b>"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q4, 2016 By the Numbers : February 24, 2017",2017-02-24 15:28:56 +0000,http://www.capitalcube.com/blog/index.php/bluebird-bio-inc-blue-us-earnings-analysis-q4-2016-by-the-numbers-february-24-2017/,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q4, 2016 By the Numbers : February 24, 2017"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Inc Highlights a Data-Rich 2017,2017-02-23 22:51:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/88hxphZZSag/bluebird-bio-inc-highlights-a-data-rich-2017-cm752423,bluebird bio NASDAQ BLUE reported fourth quarter earnings after the closing bell on Wednesday Without any products on the market the quarterly pipeline update is more important than the revenue and earnings numbers For the record the company booked 1 6 million in
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Inc Highlights a Data-Rich 2017,2017-02-23 20:54:43 +0000,http://www.fool.com/investing/2017/02/23/bluebird-bio-inc-highlights-a-data-rich-2017.aspx,bluebird bio Inc Highlights a Data-Rich 2017
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Inc Highlights a Data-Rich 2017,2017-02-23 20:54:43 +0000,http://finance.yahoo.com/r/60a1b5cf-4e1f-3b7e-a8b7-1e8ba545c73f/bluebird-bio-inc-highlights-a-data-rich-2017.aspx?yptr=yahoo&.tsrc=rss,Revenue and earnings aren't particularly important for the biotech at this stage.
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio 4Q Loss Below Street Estimates,2017-02-23 19:36:00 +0000,http://www.investopedia.com/news/bluebird-bio-4q-loss-below-street-estimates-blue/?partner=YahooSA,Bluebird Bio 4Q Loss Below Street Estimates
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio 4Q Loss Below Street Estimates,2017-02-23 19:36:00 +0000,http://finance.yahoo.com/r/7c25d57e-3ab1-3488-a085-6f8980893911/bluebird-bio-4q-loss-below-street-estimates-blue?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Bluebird's 4Q loss of $71.36 million, or $1.88 per share, was wider than analysts' loss projections."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Shares Could See Value Fly To $95 As 2017 Will Be A 'Catalyst-Filled Year',2017-02-23 12:43:43 +0000,http://finance.yahoo.com/news/bluebird-bio-shares-could-see-124343120.html?.tsrc=rss,"Wedbush’s David Nierengarten expects “several major data readouts” ahead in 2017 to act as catalysts for bluebird bio Inc (NASDAQ: BLUE ). The analyst reiterated an Outperform rating on the company, with ..."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Shares Could See Value Fly To $95 As 2017 Will Be A 'Catalyst-Filled Year',2017-02-23 12:43:43 +0000,http://finance.yahoo.com/news/bluebird-bio-shares-could-see-124343120.html,Bluebird Bio Shares Could See Value Fly To $95 As 2017 Will Be A 'Catalyst-Filled Year'
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird reports 4Q loss,2017-02-22 21:50:33 +0000,http://sg.finance.yahoo.com/news/bluebird-reports-4q-loss-215033566.html,Bluebird reports 4Q loss
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird reports 4Q loss,2017-02-22 21:50:33 +0000,http://finance.yahoo.com/news/bluebird-reports-4q-loss-215033812.html?.tsrc=rss,"On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.88. The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment ..."
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi",2017-02-22 21:17:08 +0000,http://biz.yahoo.com/e/170222/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress,2017-02-22 21:05:00 +0000,http://finance.yahoo.com/news/bluebird-bio-reports-fourth-quarter-210500469.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2016."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress,2017-02-22 21:05:00 +0000,http://finance.yahoo.com/news/bluebird-bio-reports-fourth-quarter-210500469.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2016."
BLUE,BLUE:UW,BBG004KB4FS6,Lexington's Agenus quietly discloses failure of cancer vaccine trial,2017-02-22 15:00:12 +0000,http://www.bizjournals.com/boston/news/2017/02/22/lexingtons-agenus-quietly-discloses-failure-of.html?ana=yahoo,Lexington's Agenus quietly discloses failure of cancer vaccine trial
BLUE,BLUE:UW,BBG004KB4FS6,These 4 Stocks Are Breaking Out,2017-02-15 18:52:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pPRoYVZB0xU/these-4-stocks-are-breaking-out-cm748465,"BLUEBIRD BIO, INC. ( BLUE ) is on the move, up $2.85 on Tuesday to $79.30 on 821,900 shares traded. The clinical-stage biotechnology company focuses on developing transformative gene therapies.  The stock in late January broke out of a 1-month wedge formation in which its price range had been narrowing and going"
BLUE,BLUE:UW,BBG004KB4FS6,Three Biotechs With Bullish Basing Patterns,2017-02-15 16:55:00 +0000,http://www.investopedia.com/stock-analysis/cotd/021517/three-biotechs-bullish-basing-patterns-sgen-blue-sgen-blue-crbp.aspx?partner=YahooSA,Three Biotechs With Bullish Basing Patterns
BLUE,BLUE:UW,BBG004KB4FS6,Three Biotechs With Bullish Basing Patterns,2017-02-15 16:55:00 +0000,http://finance.yahoo.com/r/af24318d-074a-35b7-8e43-4f5a8e6dba93/three-biotechs-bullish-basing-patterns-sgen-blue-sgen-blue-crbp.aspx?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Biotech stocks have roared back to life since industry executives met with the new president, allowing the group to play catch up with broad benchmarks."
BLUE,BLUE:UW,BBG004KB4FS6,"Cooperman's Omega Advisors: Out With Chesapeake; In With Amazon, Bluebird",2017-02-14 16:53:00 +0000,http://blogs.barrons.com/focusonfunds/2017/02/14/coopermans-omega-advisors-out-with-chesapeake-in-with-amazon-bluebird/?mod=yahoobarrons&ru=yahoo,"Cooperman's Omega Advisors: Out With Chesapeake; In With Amazon, Bluebird"
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement",2017-02-13 21:07:51 +0000,http://biz.yahoo.com/e/170213/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement"
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Stock Surged 20.7% Higher in January,2017-02-09 22:19:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PDhmsSYca-s/why-bluebird-bio-stock-surged-207-higher-in-january-cm745858,What happened After updating investors on its wide ranging gene therapy research program at a key industry conference early in the month 160 shares of bluebird bio NASDAQ BLUE surged 20 7 higher in January 160 according to S amp P Global Market Intelligence So
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Stock Surged 20.7% Higher in January,2017-02-09 20:21:05 +0000,http://finance.yahoo.com/r/b9b9dc33-0398-3df6-8031-b79e87d7f479/why-bluebird-bio-stock-surged-207-higher-in-januar.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2&yptr=yahoo&.tsrc=rss,Optimism soared after management updated investors on the progress it's making on its clinical-stage gene therapy pipeline.
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Stock Surged 20.7% Higher in January,2017-02-09 20:21:05 +0000,http://www.fool.com/investing/2017/02/09/why-bluebird-bio-stock-surged-207-higher-in-januar.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why bluebird bio Stock Surged 20.7% Higher in January
BLUE,BLUE:UW,BBG004KB4FS6,3 Scorching Hot Biotech Stocks -- Are They Buys?,2017-02-08 23:18:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lpKiuq-DIDA/3-scorching-hot-biotech-stocks-are-they-buys-cm745212,Making a 70 return in only three months sounds pretty good Three biotech stocks have done just that and more Shares of Clovis Oncology NASDAQ CLVS soared over 120 during the last three months Bluebird bio s NASDAQ BLUE stock jumped more than 80 during the period
BLUE,BLUE:UW,BBG004KB4FS6,3 Scorching Hot Biotech Stocks -- Are They Buys?,2017-02-08 21:53:03 +0000,http://finance.yahoo.com/r/5d7f3696-644a-3626-b913-614d1ed939a1/3-scorching-hot-biotech-stocks-are-they-buys.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2&yptr=yahoo&.tsrc=rss,"Are Clovis Oncology, bluebird bio, and Exelixis still good biotech stock picks after their huge gains?"
BLUE,BLUE:UW,BBG004KB4FS6,3 Scorching Hot Biotech Stocks -- Are They Buys?,2017-02-08 21:53:03 +0000,http://www.fool.com/investing/2017/02/08/3-scorching-hot-biotech-stocks-are-they-buys.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Scorching Hot Biotech Stocks -- Are They Buys?
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2017-02-03 13:19:43 +0000,http://biz.yahoo.com/e/170203/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BLUE,BLUE:UW,BBG004KB4FS6,Harry Boxer: Watch these two biotechnology stocks,2017-02-03 13:14:34 +0000,http://finance.yahoo.com/r/8ae33069-7c03-37c1-8ccc-5fde1f9184a5/Story.aspx?guid=DAA73EFC-E989-11E6-B405-ED2198D7EFEF&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Gene-therapy company bluebird bio and cannabis-based biotech firm Cara Therapeutics break out with big moves.
BLUE,BLUE:UW,BBG004KB4FS6,Harry Boxer: Watch these two biotechnology stocks,2017-02-03 13:14:34 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=DAA73EFC-E989-11E6-B405-ED2198D7EFEF&siteid=yhoof2,Harry Boxer: Watch these two biotechnology stocks
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease,2017-02-03 13:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-announces-first-patient-130000772.html?.tsrc=rss,"bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced treatment of the first patient under the amended study protocol in HGB-206, the company’s Phase 1 study of its LentiGlobin Drug Product in patients with severe sickle cell disease ."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease,2017-02-03 13:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-announces-first-patient-130000772.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced treatment of the first patient under the amended study protocol in HGB-206, the company’s Phase 1 study of its LentiGlobin Drug Product in patients with severe sickle cell disease ."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Looks Set to Soar Upward,2017-01-31 14:03:00 +0000,http://realmoney.thestreet.com/articles/01/31/2017/bluebird-bio-looks-set-soar-upward?puc=yahoo&cm_ven=YAHOO,Bluebird Bio Looks Set to Soar Upward
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. – Value Analysis (NASDAQ:BLUE) : January 24, 2017",2017-01-24 15:08:49 +0000,http://www.capitalcube.com/blog/index.php/bluebird-bio-inc-value-analysis-nasdaqblue-january-24-2017/,"bluebird bio, Inc. – Value Analysis (NASDAQ:BLUE) : January 24, 2017"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : January 23, 2017",2017-01-23 13:28:05 +0000,http://www.capitalcube.com/blog/index.php/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bearish-manner-blue-us-january-23-2017/,"bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : January 23, 2017"
BLUE,BLUE:UW,BBG004KB4FS6,"Commit To Purchase bluebird bio At $45, Earn 22.2% Using Options",2017-01-19 19:38:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oLRiikw8_gA/commit-to-purchase-bluebird-bio-at-45-earn-222-using-options-cm735611,Investors considering a purchase of bluebird bio Inc Symbol BLUE stock but tentative about paying the going market price of 65 80 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
BLUE,BLUE:UW,BBG004KB4FS6,Vetr Crowd Upgrades Bluebird After Trump Presser,2017-01-11 22:13:33 +0000,http://finance.yahoo.com/news/vetr-crowd-upgrades-bluebird-trump-221333642.html,Vetr Crowd Upgrades Bluebird After Trump Presser
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan",2017-01-09 13:03:11 +0000,http://biz.yahoo.com/e/170109/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan"
BLUE,BLUE:UW,BBG004KB4FS6,These 5 Biotech Stocks Could Be Big Takeover Targets in 2017,2017-01-06 13:35:11 +0000,http://finance.yahoo.com/news/5-biotech-stocks-could-big-133511110.html,These 5 Biotech Stocks Could Be Big Takeover Targets in 2017
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference,2017-01-04 13:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-present-35th-annual-130000560.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced today that Nick Leschly, chief bluebird, will present at the 35th annual J.P."
BLUE,BLUE:UW,BBG004KB4FS6,3 Small Biotech Stocks That Big Biotechs Like,2016-12-19 20:09:24 +0000,http://www.fool.com/investing/2016/12/18/3-small-biotech-stocks-that-big-biotechs-like.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Small Biotech Stocks That Big Biotechs Like
BLUE,BLUE:UW,BBG004KB4FS6,3 Small Biotech Stocks That Big Biotechs Like,2016-12-18 21:56:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tjGNwPZcnwM/3-small-biotech-stocks-that-big-biotechs-like-cm723018,Sometimes little dogs get to run with the big dogs That s the case for three small biotechs Cytokinetics NASDAQ CYTK bluebird bio NASDAQ BLUE and Galapagos NASDAQ GLPG Here s why big biotechs Amgen NASDAQ AMGN Celgene NASDAQ CELG and
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-12-15 13:16:06 +0000,http://biz.yahoo.com/e/161215/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement,2016-12-15 13:00:00 +0000,http://uk.finance.yahoo.com/news/bluebird-bio-apceth-biopharma-establish-130000327.html,bluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement
BLUE,BLUE:UW,BBG004KB4FS6,Better Buy: Intrexon Corporation vs. bluebird bio,2016-12-14 13:36:26 +0000,http://www.fool.com/investing/2016/12/13/better-buy-intrexon-corporation-vs-bluebird-bio.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Intrexon Corporation vs. bluebird bio
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-12-14 13:16:13 +0000,http://biz.yahoo.com/e/161214/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product in Northstar-2 (HGB-207) Phase 3 Trial of Patients with Transfusion-Dependent β-Thalassemia,2016-12-14 13:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-announces-first-patient-130000065.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced treatment of the first patient in Northstar-2, the Phase 3 study of its LentiGlobin drug product in patients with transfusion-dependent β-thalassemia and non-β0/β0 genotypes."
BLUE,BLUE:UW,BBG004KB4FS6,Better Buy: Intrexon Corporation vs. bluebird bio,2016-12-13 16:58:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TLFZ0XUEnGI/better-buy-intrexon-corporation-vs-bluebird-bio-cm720837,Image source Getty Images Although the word biotech is often used interchangeably with biopharma biology as technology is not confined to healthcare applications That s the message engineered biology conglomerate Intrexon NYSE XON is trying to send out to investors Sure
BLUE,BLUE:UW,BBG004KB4FS6,"Better Buy: bluebird bio, Inc. vs. Kite Pharma",2016-12-10 20:50:22 +0000,http://www.fool.com/investing/2016/12/09/better-buy-bluebird-bio-inc-vs-kite-pharma.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: bluebird bio, Inc. vs. Kite Pharma"
BLUE,BLUE:UW,BBG004KB4FS6,"Better Buy: bluebird bio, Inc. vs. Kite Pharma",2016-12-09 21:56:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1JoPM2t0iUQ/better-buy-bluebird-bio-inc-vs-kite-pharma-cm719582,Several clinical stage biotechs are developing therapies using 160 chimeric antigen receptor T cells CAR T Two of them in particular have enjoyed some good news in 2016 bluebird bio NASDAQ BLUE and Kite Pharma NASDAQ KITE Which of these two up and coming biotechs is
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Smartly Strikes While the Iron Is Hot,2016-12-09 13:00:06 +0000,http://www.bloomberg.com/gadfly/articles/2016-12-09/bluebird-bio-share-sale-perfect-timing?cmpid=yhoo.headline,Bluebird Smartly Strikes While the Iron Is Hot
BLUE,BLUE:UW,BBG004KB4FS6,"Why Flotek Industries, Oxford Industries, and bluebird bio Slumped Today",2016-12-08 01:56:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_bEhksQncqU/why-flotek-industries-oxford-industries-and-bluebird-bio-slumped-today-cm718396,Wednesday was a strong day for the stock market as investors continued to be optimistic about the future of the U S economy Major market benchmarks climbed more strongly than in sessions earlier in the week with gains of 1 or more sending both the S amp P 500 and the Dow
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc. Slipped Lower Today,2016-12-07 23:56:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/39u4K2fwNCk/why-bluebird-bio-inc-slipped-lower-today-cm718360,Image source Getty Images What happened bluebid bio NASDAQ BLUE ended the day down 10 7 after raising approximately 250 million selling shares in a secondary offering So what Companies usually trade lower after a secondary offering since the dilution
BLUE,BLUE:UW,BBG004KB4FS6,Global Blood Therapeutics: Short-Sellers Could Be In For A Ride,2016-12-07 23:56:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l60U57gQQA8/global-blood-therapeutics-short-sellers-could-be-in-for-a-ride-cm718328,By Decision Analytics ByDecision Analytics I have written about Global Blood Therapeutics GBT before here In my prior article I addressed a number of fairly legitimate concerns people have cited about the stock and its lead drug for sickle cell disease SCD called GBT 440 and
BLUE,BLUE:UW,BBG004KB4FS6,"Why Flotek Industries, Oxford Industries, and bluebird bio Slumped Today",2016-12-07 23:55:00 +0000,http://www.fool.com/investing/2016/12/07/why-flotek-industries-oxford-industries-and-bluebi.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Flotek Industries, Oxford Industries, and bluebird bio Slumped Today"
BLUE,BLUE:UW,BBG004KB4FS6,Why You Should Let Celgene Corporation Invest Your Money,2016-12-07 22:58:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SYy5mJ8y19A/why-you-should-let-celgene-corporation-invest-your-money-cm718334,How would you like to have an investment manager who quadrupled your initial investment over the last 10 years That s the return that Celgene Corporation NASDAQ CELG achieved But Celgene is a biotech not an investment manager right Actually it s both The company has
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc. Slipped Lower Today,2016-12-07 22:05:09 +0000,http://www.fool.com/investing/2016/12/07/why-bluebird-bio-inc-slipped-lower-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why bluebird bio Inc. Slipped Lower Today
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements",2016-12-07 21:24:14 +0000,http://biz.yahoo.com/e/161207/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements"
BLUE,BLUE:UW,BBG004KB4FS6,Drug Stocks Topple On Donald Trump's Pledge To Bring Down Drug Prices,2016-12-07 21:12:13 +0000,http://www.investors.com/research/ibd-industry-themes/biotechs-topple-on-donald-trumps-pledge-to-bring-down-drug-prices/,Drug Stocks Topple On Donald Trump's Pledge To Bring Down Drug Prices
BLUE,BLUE:UW,BBG004KB4FS6,"Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally",2016-12-07 19:46:00 +0000,https://www.thestreet.com/story/13917873/1/dow-looks-again-at-a-record-as-wall-street-shakes-off-biotech-slump.html?puc=yahoo&cm_ven=YAHOO,"Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally"
BLUE,BLUE:UW,BBG004KB4FS6,"Wednesday Sector Laggards: Drugs, Biotechnology Stocks",2016-12-07 18:56:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NfceRJdoDV4/wednesday-sector-laggards-drugs-biotechnology-stocks-cm718164,In trading on Wednesday drugs shares were relative laggards down on the day by about 2 7 Helping drag down the group were shares of Repros Therapeutics RPRX down about 10 5 and shares of Blueprint Medicines BPMC down about 9 6 on the day Also lagging the market Wednesday
BLUE,BLUE:UW,BBG004KB4FS6,"Wednesday's ETF Movers: GDXJ, XBI",2016-12-07 18:56:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jffro8m8QT0/wednesdays-etf-movers-gdxj-xbi-cm718160,In trading on Wednesday the Junior Gold Miners ETF GDXJ is outperforming other ETFs up about 2 6 on the day Components of that ETF showing particular strength include shares of Asanko Gold AKG CA up about 6 8 and shares of B2gold BTG up about 5 4 on the day
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Blood Disorder Drug Study Went Well (BLUE),2016-12-07 16:31:00 +0000,http://www.investopedia.com/news/bluebirds-blood-disorder-drug-did-well-trial-blue/?partner=YahooSA,Bluebird Blood Disorder Drug Study Went Well (BLUE)
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Expects $250M From Stock Offering (BLUE),2016-12-07 15:40:00 +0000,http://www.investopedia.com/news/bluebird-bio-sets-250m-common-stock-offering-blue/?partner=YahooSA,Bluebird Expects $250M From Stock Offering (BLUE)
BLUE,BLUE:UW,BBG004KB4FS6,"Pre-Market Most Active for Dec 7, 2016 :  TER, RAD, MT, PBR, BAC, VALE, MU, AAPL, TVIX, TLT, XIV, BLUE",2016-12-07 13:56:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f10E2S_GqUM/pre-market-most-active-for-dec-7-2016-ter-rad-mt-pbr-bac-vale-mu-aapl-tvix-tlt-xiv-blue-cm717834,The NASDAQ 100 Pre Market Indicator is down 7 73 to 4 780 94 The total Pre Market volume is currently 16 236 861 shares traded The following are the most active stocks for the pre market session Teradyne Inc TER is 0 7 at 25 67 with 4 208 610 shares traded TER
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Pricing of Public Offering of Common Stock,2016-12-07 02:49:00 +0000,http://finance.yahoo.com/news/bluebird-bio-announces-pricing-public-024900833.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of 3,289,473 shares of its common stock at a public offering price of $76.00 per share, before underwriting discounts."
BLUE,BLUE:UW,BBG004KB4FS6,"Rivals Kite Pharma, Juno Therapeutics Tank On Cancer Data; Spark Flies",2016-12-06 21:31:24 +0000,http://www.investors.com/news/technology/rivals-kite-pharma-juno-therapeutics-tank-on-cancer-data-spark-flies/,"Rivals Kite Pharma, Juno Therapeutics Tank On Cancer Data; Spark Flies"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Proposed Public Offering of Common Stock,2016-12-06 21:19:00 +0000,http://finance.yahoo.com/news/bluebird-bio-announces-proposed-public-211900417.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an underwritten public offering of $200 million of its common stock."
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events",2016-12-06 11:04:14 +0000,http://biz.yahoo.com/e/161206/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Inc Presents New Data from HGB-205 Study of LentiGlobin(TM) at American Society of Hematology Annual Meeting scheduled for 11:30 pm ET today,2016-12-06 04:30:00 +0000,http://biz.yahoo.com/cc/7/155037.html,bluebird bio Inc Presents New Data from HGB-205 Study of LentiGlobin(TM) at American Society of Hematology Annual Meeting scheduled for 11:30 pm ET today
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Provides Updates on HSC Gene Therapy Programs,2016-12-06 00:30:00 +0000,http://finance.yahoo.com/news/bluebird-bio-provides-updates-hsc-003000675.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunothe"
BLUE,BLUE:UW,BBG004KB4FS6,Positive sentiment in biotech post-election,2016-12-05 18:55:00 +0000,http://finance.yahoo.com/video/positive-sentiment-biotech-post-election-185500952.html,Positive sentiment in biotech post-election
BLUE,BLUE:UW,BBG004KB4FS6,Celgene CEO: Excited by opportunities corporate tax refor...,2016-12-05 16:16:00 +0000,http://finance.yahoo.com/video/celgene-ceo-excited-opportunities-corporate-161600631.html,Celgene CEO: Excited by opportunities corporate tax refor...
BLUE,BLUE:UW,BBG004KB4FS6,"ALNY In Motion, Shire Finds New Use For Old Drug, TFX Snaps Up VASC",2016-12-05 00:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GPggaNQCUwk/alny-in-motion-shire-finds-new-use-for-old-drug-tfx-snaps-up-vasc-20161205-00008,"ALNY In Motion, Shire Finds New Use For Old Drug, TFX Snaps Up VASC"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting,2016-12-03 17:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-presents-data-hgb-170000659.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced the presentation of new data from the ongoing HGB-205 clinical study evaluating its LentiGlobin product candidate in patients with transfusion-dependent β-thalassemia and severe sickle cell disease at the 58th ..."
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Shares Rallied 24.7% In November,2016-12-03 12:41:07 +0000,http://www.fool.com/investing/2016/12/03/why-bluebird-bio-shares-rallied-247-in-november.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why bluebird bio Shares Rallied 24.7% In November
BLUE,BLUE:UW,BBG004KB4FS6,Adventures in CAR-T Racing: Crashes and Curves Edition,2016-12-02 16:20:01 +0000,http://www.fool.com/investing/2016/12/02/adventures-in-car-t-racing-crashes-and-curves-edit.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Adventures in CAR-T Racing: Crashes and Curves Edition
BLUE,BLUE:UW,BBG004KB4FS6,bluebird Stock Up on Positive Interim Multiple Myeloma Data,2016-12-02 14:00:02 +0000,http://finance.yahoo.com/news/bluebird-stock-positive-interim-multiple-140002717.html,bluebird Stock Up on Positive Interim Multiple Myeloma Data
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Change in Directors or Principal Officers",2016-12-02 13:31:26 +0000,http://biz.yahoo.com/e/161202/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Change in Directors or Principal Officers"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Management Appointments,2016-12-02 13:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-announces-management-appointments-130000870.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced two new appointments as part of the company’s ongoing preparation for commercial readiness."
BLUE,BLUE:UW,BBG004KB4FS6,Cramer issues a warning on biotech stocks — there's new risk that you need to consider,2016-12-02 00:03:26 +0000,http://www.cnbc.com/id/104137986?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104137986,Cramer issues a warning on biotech stocks — there's new risk that you need to consider
BLUE,BLUE:UW,BBG004KB4FS6,"Why General Motors, bluebird bio, and Skechers USA Jumped Today",2016-12-01 23:33:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CLfmksR-mQ4/why-general-motors-bluebird-bio-and-skechers-usa-jumped-today-cm716707,Thursday continued an unusual situation in the stock market with massive sector rotations having opposite impacts on different major market benchmarks The Dow was up more than a third of a percent climbing on the strength of various energy and financial stocks in the average Yet
BLUE,BLUE:UW,BBG004KB4FS6,Cramer issues a warning on biotech stocks — there's new r...,2016-12-01 23:25:00 +0000,http://finance.yahoo.com/video/cramer-issues-warning-biotech-stocks-232500886.html,Cramer issues a warning on biotech stocks — there's new r...
BLUE,BLUE:UW,BBG004KB4FS6,A Potentially Astounding Advance in Multiple Myeloma,2016-12-01 22:36:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pRzb5ADoEtg/a-potentially-astounding-advance-in-multiple-myeloma-cm716665,Multiple myeloma is a B cell cancer caused by malignant plasma cells It s a tough to treat cancer with many patients undergoing multiple treatments over time Eventually patients whose disease returns despite receiving multiple prior treatments are left with few treatment
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Rockets On Myeloma Drug; Celgene Gets Boost,2016-12-01 22:00:03 +0000,http://www.investors.com/news/technology/bluebird-rockets-on-most-potent-myeloma-drug-celgene-gets-boost/,Bluebird Rockets On Myeloma Drug; Celgene Gets Boost
BLUE,BLUE:UW,BBG004KB4FS6,A Potentially Astounding Advance in Multiple Myeloma,2016-12-01 20:40:00 +0000,http://www.fool.com/investing/2016/12/01/a-potentially-astounding-advance-in-multiple-myelo.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,A Potentially Astounding Advance in Multiple Myeloma
BLUE,BLUE:UW,BBG004KB4FS6,Here's Why Bluebird Bio (BLUE) is Rallying Today,2016-12-01 20:33:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WZ65Qvreclk/heres-why-bluebird-bio-blue-is-rallying-today-cm716578,On Thursday shares of biotech company Bluebird Bio Inc BLUE are rallying up over 17 in midday trading after positive results came in for its experimental anti BCMA CAR chimeric antigen receptor T cell product candidate 160 bb2121 in an early stage study for relapsed refractory
BLUE,BLUE:UW,BBG004KB4FS6,Here's Why Bluebird Bio (BLUE) is Rallying Today,2016-12-01 18:58:06 +0000,http://finance.yahoo.com/news/heres-why-bluebird-bio-blue-185806350.html,Here's Why Bluebird Bio (BLUE) is Rallying Today
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Myeloma Cancer Drug Does Well (BLUE),2016-12-01 17:07:00 +0000,http://www.investopedia.com/news/bluebird-bio-buoyed-myeloma-drug-success-blue/?partner=YahooSA,Bluebird Bio Myeloma Cancer Drug Does Well (BLUE)
BLUE,BLUE:UW,BBG004KB4FS6,Here’s What’s So Important About The bluebird bio Inc (BLUE) Data,2016-12-01 16:42:45 +0000,http://www.insidermonkey.com/blog/heres-whats-so-important-about-the-bluebird-bio-inc-blue-data-495840/,Here’s What’s So Important About The bluebird bio Inc (BLUE) Data
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma,2016-12-01 15:22:20 +0000,http://www.publicnow.com/view/997E3F5BD98F93D4E995CE90C5FC2EE67CD53609,"[at noodls] - - 100% of patients (n=6) in second and third dose cohorts achieved an objective response; two patients MRD-negative; overall response rate (ORR) is 78% - - Two patients achieved stringent complete responses, ..."
BLUE,BLUE:UW,BBG004KB4FS6,"Why bluebird bio, Inc. Stock Is Soaring Today",2016-12-01 15:19:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N7uv8SWFoD8/why-bluebird-bio-inc-stock-is-soaring-today-cm716236,Image source Getty Images What happened Shares of the clinical stage biotech bluebird bio Inc NASDAQ BLUE rose by more than 24 in pre market trading today as a result of its experimental anti BCMA CAR T chimeric antigen receptor T cell 160 cell
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird bio stock gains on impressive early cancer trial results,2016-12-01 15:05:08 +0000,http://www.bizjournals.com/boston/news/2016/12/01/bluebird-bio-stock-gains-on-impressive-early.html?ana=yahoo,Bluebird bio stock gains on impressive early cancer trial results
BLUE,BLUE:UW,BBG004KB4FS6,"Bluebird Bio, Celgene Multiple Myeloma Therapy Strong In 9-Patient Study",2016-12-01 14:40:07 +0000,http://www.investors.com/news/technology/bluebird-bio-celgene-multiple-myeloma-therapy-strong-in-9-patient-study/,"Bluebird Bio, Celgene Multiple Myeloma Therapy Strong In 9-Patient Study"
BLUE,BLUE:UW,BBG004KB4FS6,Stock Futures Flat Ahead of Manufacturing Data,2016-12-01 14:35:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R0bzRC4gFRQ/stock-futures-flat-ahead-of-manufacturing-data-cm716229,U S stock futures were straddling the flat line into Thursday s open a day after the Dow Jones Industrial Average and S amp P 500 set new record highs and ahead of Friday s pivotal labor market report Another day higher in oil futures is keeping the energy sector afloat while losses in
BLUE,BLUE:UW,BBG004KB4FS6,"Why bluebird bio, Inc. Stock Is Soaring Today",2016-12-01 14:11:00 +0000,http://www.fool.com/investing/2016/12/01/why-bluebird-bio-inc-stock-is-soaring-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why bluebird bio, Inc. Stock Is Soaring Today"
BLUE,BLUE:UW,BBG004KB4FS6,"Pre-Market Most Active for Dec 1, 2016 :  VALE, VCIT, CHK, WLL, TLN, PBR, VOD, SDRL, BLUE, BOJA, XIV, TVIX",2016-12-01 13:55:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/54vGYVlBsNI/pre-market-most-active-for-dec-1-2016-vale-vcit-chk-wll-tln-pbr-vod-sdrl-blue-boja-xiv-tvix-cm716211,The NASDAQ 100 Pre Market Indicator is up 82 to 4 811 63 The total Pre Market volume is currently 4 207 388 shares traded The following are the most active stocks for the pre market session VALE S A VALE is 0 19 at 8 68 with 1 559 720 shares traded VALE s
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Inc Conference Call on Interim Phase 1 Dose Escalation Data scheduled for 8:00 am ET today,2016-12-01 13:00:00 +0000,http://biz.yahoo.com/cc/1/155021.html,bluebird bio Inc Conference Call on Interim Phase 1 Dose Escalation Data scheduled for 8:00 am ET today
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird's Encouraging Myeloma Data Not Enough For Cantor To Lift Its Sell Rating,2016-12-01 12:59:14 +0000,http://finance.yahoo.com/news/bluebirds-encouraging-myeloma-data-not-125914687.html,Bluebird's Encouraging Myeloma Data Not Enough For Cantor To Lift Its Sell Rating
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio CEO on new study data: We're getting profoun...,2016-12-01 11:38:00 +0000,http://finance.yahoo.com/video/bluebird-bio-ceo-study-data-113800325.html,Bluebird Bio CEO on new study data: We're getting profoun...
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Inc. (BLUE) Is Up Sharply On Multiple Myeloma Study Results,2016-12-01 09:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YjAp80EfBeI/bluebird-bio-inc-blue-is-up-sharply-on-multiple-myeloma-study-results-20161201-00684,Bluebird Bio Inc. (BLUE) Is Up Sharply On Multiple Myeloma Study Results
BLUE,BLUE:UW,BBG004KB4FS6,"It's All Green For BLUE, HTBX Plunges On Failed Study, Watch Out For BPMC",2016-12-01 00:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tDge2q3p8Iw/its-all-green-for-blue-htbx-plunges-on-failed-study-watch-out-for-bpmc-20161201-00015,"It's All Green For BLUE, HTBX Plunges On Failed Study, Watch Out For BPMC"
BLUE,BLUE:UW,BBG004KB4FS6,"Bluebird, Celgene myeloma treatment impresses in tiny study",2016-11-30 22:53:19 +0000,http://finance.yahoo.com/news/bluebird-celgene-myeloma-treatment-impresses-225319255.html,"Bluebird, Celgene myeloma treatment impresses in tiny study"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma,2016-11-30 22:27:00 +0000,http://finance.yahoo.com/news/bluebird-bio-announces-interim-phase-222700149.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that interim data from its ongoing Phase 1 clinical study of bb2121, the company’s investigational anti-BCMA CAR T cell product candidate in patients with relapsed/refractory multiple myeloma, will be presented ..."
BLUE,BLUE:UW,BBG004KB4FS6,"Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects",2016-11-30 22:20:00 +0000,https://www.thestreet.com/story/13909407/1/bluebird-celgene-t-cell-therapy-eliminates-multiple-myeloma-with-minimal-side-effects.html?puc=yahoo&cm_ven=YAHOO,"Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects"
BLUE,BLUE:UW,BBG004KB4FS6,3 Biotechs With Save-the-Date Catalysts on Tap,2016-11-30 17:34:00 +0000,http://www.fool.com/investing/2016/11/29/3-biotechs-with-save-the-date-catalysts-on-tap.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotechs With Save-the-Date Catalysts on Tap
BLUE,BLUE:UW,BBG004KB4FS6,Is bluebird bio Inc (BLUE) A Good Stock To Buy?,2016-11-27 23:41:36 +0000,http://www.insidermonkey.com/blog/is-bluebird-bio-inc-blue-a-good-stock-to-buy-493068/,Is bluebird bio Inc (BLUE) A Good Stock To Buy?
BLUE,BLUE:UW,BBG004KB4FS6,Why Juno Therapeutics Inc Plummeted Today,2016-11-23 21:05:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2TYIuyEcYjE/why-juno-therapeutics-inc-plummeted-today-cm713527,Image source Getty Images What happened Juno Therapeutics NASDAQ JUNO is down 26 6 at 1 26 p m EST after announcing that it was placing a hold on one of its CAR T clinical trials after two patients suffered cerebral edemas earlier this week Both have died
BLUE,BLUE:UW,BBG004KB4FS6,Why Juno Therapeutics Inc Plummeted Today,2016-11-23 19:09:55 +0000,http://www.fool.com/investing/2016/11/23/why-juno-therapeutics-inc-plummeted-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Juno Therapeutics Inc Plummeted Today
BLUE,BLUE:UW,BBG004KB4FS6,"Analysts say Juno's stock tumbles shouldn't spill over to Bluebird, Kite Pharma shares",2016-11-23 15:16:27 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=DD79EBA5-32B4-4627-8943-E15E4AFD3150&siteid=yhoof2,"Analysts say Juno's stock tumbles shouldn't spill over to Bluebird, Kite Pharma shares"
BLUE,BLUE:UW,BBG004KB4FS6,Better Buy: Juno Therapeutics vs. bluebird bio,2016-11-18 21:23:31 +0000,http://www.fool.com/investing/2016/11/17/better-buy-juno-therapeutics-vs-bluebird-bio.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Juno Therapeutics vs. bluebird bio
BLUE,BLUE:UW,BBG004KB4FS6,Better Buy: Juno Therapeutics vs. bluebird bio,2016-11-17 22:50:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vGyfin9O4qY/better-buy-juno-therapeutics-vs-bluebird-bio-cm710879,Image source Getty Images This round of our ongoing Better Buy series pits two up and coming biotechs Juno Therapeutics NASDAQ JUNO and bluebird bio NASDAQ BLUE against each other Platforms in the making Both Juno Therapeutics and Bluebird are developing
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : November 15, 2016",2016-11-15 12:37:27 +0000,http://www.capitalcube.com/blog/index.php/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bullish-manner-blue-us-november-15-2016/,"bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : November 15, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,"FDA Snubs DVAX, Keep An Eye On OCUL, It's All Green For BLUE",2016-11-15 01:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_6PcBqSY1LI/fda-snubs-dvax-keep-an-eye-on-ocul-its-all-green-for-blue-20161115-00028,"FDA Snubs DVAX, Keep An Eye On OCUL, It's All Green For BLUE"
BLUE,BLUE:UW,BBG004KB4FS6,"FDA Snubs DVAX, Keep An Eye On OCUL, It''s All Green For BLUE",2016-11-15 01:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5kdvVrziyXY/fda-snubs-dvax-keep-an-eye-on-ocul-its-all-green-for-blue-20161115-00027,"FDA Snubs DVAX, Keep An Eye On OCUL, It''s All Green For BLUE"
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc. Stock Jumped Today,2016-11-14 21:09:50 +0000,http://www.fool.com/investing/2016/11/14/why-bluebird-bio-inc-stock-jumped-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why bluebird bio Inc. Stock Jumped Today
BLUE,BLUE:UW,BBG004KB4FS6,"ETFs with exposure to bluebird bio, Inc. : November 14, 2016",2016-11-14 17:58:08 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-bluebird-bio-inc-november-14-2016/,"ETFs with exposure to bluebird bio, Inc. : November 14, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-11-14 15:27:39 +0000,http://biz.yahoo.com/e/161114/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present New Data from Novel Anti-BCMA CAR T Cell Therapy bb2121 at EORTC-NCI-AACR Molecular Targets and Cancer Therapies Symposium,2016-11-14 14:57:00 +0000,http://finance.yahoo.com/news/bluebird-bio-present-data-novel-145700409.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that interim data from its study of bb2121, the company’s anti-BCMA CAR T cell therapy, currently in a Phase 1 trial of patients with relapsed/refractory multiple myeloma will be presented at the EORTC-NCI-AACR ..."
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016",2016-11-11 15:44:06 +0000,http://www.capitalcube.com/blog/index.php/bluebird-bio-inc-blue-us-earnings-analysis-q3-2016-by-the-numbers-november-11-2016/,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,727.6 Million Reasons bluebird bio Inc. Has Time to Figure It Out,2016-11-10 19:45:48 +0000,http://www.fool.com/investing/2016/11/09/728-million-reasons-bluebird-bio-inc-has-time-to.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,727.6 Million Reasons bluebird bio Inc. Has Time to Figure It Out
BLUE,BLUE:UW,BBG004KB4FS6,"Why bluebird bio, Inc. Stock Got Crushed in October",2016-11-10 15:55:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1noDFOOp_qE/why-bluebird-bio-inc-stock-got-crushed-in-october-cm707191,Image source Getty Images What happened Shares of the gene therapy company bluebird bio Inc NASDAQ BLUE were flat out routed in October dropping by more than 35 160 according to data from S amp P Global Market Intelligence Bluebird s sizable downturn even
BLUE,BLUE:UW,BBG004KB4FS6,"Why bluebird bio, Inc. Stock Got Crushed in October",2016-11-10 14:46:06 +0000,http://www.fool.com/investing/2016/11/10/why-bluebird-bio-inc-stock-got-crushed-in-october.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why bluebird bio, Inc. Stock Got Crushed in October"
BLUE,BLUE:UW,BBG004KB4FS6,727.6 Million Reasons bluebird bio Inc. Has Time to Figure It Out,2016-11-09 20:54:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j2Zz7aps38k/7276-million-reasons-bluebird-bio-inc-has-time-to-figure-it-out-cm706731,Image source Getty Images bluebird bio NASDAQ BLUE released earnings last week as it so often does without warning or a conference call to discuss the quarter Bluebird results The only number that really matters
BLUE,BLUE:UW,BBG004KB4FS6,Why These Biotechs Saw Double-Digit Gains Today,2016-11-09 19:25:20 +0000,http://www.fool.com/investing/2016/11/09/why-these-biotechs-saw-double-digit-gains-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why These Biotechs Saw Double-Digit Gains Today
BLUE,BLUE:UW,BBG004KB4FS6,Global Blood Therapeutics: Incredible Value At This Price,2016-11-07 18:55:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XP0skoMpVtc/global-blood-therapeutics-incredible-value-at-this-price-cm698712,By Decision Analytics ByDecision Analytics Every once in a while I come across a biotech stock that seems so incredibly undervalued I think it has to be wrong So I try to make sense of it Often I find a big red flag like increasing competition market decline or a high likelihood
BLUE,BLUE:UW,BBG004KB4FS6,"Bluebird Bio 3Q Loss $77M, or $2.07 a Share (BLUE)",2016-11-05 21:57:00 +0000,http://www.investopedia.com/news/bluebird-bio-3q-loss-207shr-below-street-blue/?partner=YahooSA,"Bluebird Bio 3Q Loss $77M, or $2.07 a Share (BLUE)"
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc. Got Knocked Down Today,2016-11-03 19:08:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9mqpPy0FA00/why-bluebird-bio-inc-got-knocked-down-today-cm703564,Image source Getty Images What happened bluebird bio NASDAQ BLUE is down 12 at 12 21 p m EDT after abstracts for next month s American Society of Hematology ASH meeting were released this morning The biotech also released earnings yesterday afternoon but as
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc. Got Knocked Down Today,2016-11-03 17:27:35 +0000,http://www.fool.com/investing/2016/11/03/why-bluebird-bio-inc-got-knocked-down-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why bluebird bio Inc. Got Knocked Down Today
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-11-03 13:11:32 +0000,http://biz.yahoo.com/e/161103/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present New Data from Three LentiGlobinTM Clinical Studies at American Society of Hematology (ASH) Annual Meeting,2016-11-03 13:00:00 +0000,http://finance.yahoo.com/news/bluebird-bio-present-data-three-130000368.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that data from its ongoing clinical studies of LentiGlobin drug product in transfusion-dependent β-thalassemia and severe sickle cell disease will be highlighted in oral and poster presentations at the 58th ..."
BLUE,BLUE:UW,BBG004KB4FS6,3 Top Biotech Stocks to Buy in November,2016-11-02 21:08:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wdQ-hSCMES0/3-top-biotech-stocks-to-buy-in-november-cm702818,Image source Getty Images Like Rodney Dangerfield the biotech sector isn t getting a lot of respect these days The iShares Nasdaq Biotech ETF NASDAQ IBB a popular exchange traded fund that owns a wide range of biotech stocks is down 24 year to date which badly trails
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi",2016-11-02 20:25:09 +0000,http://biz.yahoo.com/e/161102/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reports Third Quarter 2016 Financial Results and Recent Operational Progress,2016-11-02 20:21:41 +0000,http://www.publicnow.com/view/F60CA365FE533E25145E1A7A0A0E50B0C925D4D5,[at noodls] - - Initiated HGB-207 Phase 3 study of LentiGlobin™ drug product in patients with transfusion-dependent beta-thalassemia (TDT) with non β/βgenotypes - - HGB-207 and all studies of LentiGlobin to incorporate ...
BLUE,BLUE:UW,BBG004KB4FS6,3 Top Biotech Stocks to Buy in November,2016-11-02 19:47:14 +0000,http://www.fool.com/investing/2016/11/02/3-top-biotech-stocks-to-buy-in-november.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Biotech Stocks to Buy in November
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Two Investor Conferences in November,2016-11-01 20:28:37 +0000,http://www.publicnow.com/view/237DE219726F3C91BEA1D4FF402C58DC99DC1B5A,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 1, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases ..."
BLUE,BLUE:UW,BBG004KB4FS6,Notable Two Hundred Day Moving Average Cross - BLUE,2016-10-27 18:41:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8xNVRWvPswk/notable-two-hundred-day-moving-average-cross-blue-cm699641,In trading on Thursday shares of bluebird bio Inc Symbol BLUE crossed below their 200 day moving average of 49 95 changing hands as low as 49 75 per share bluebird bio Inc shares are currently trading off about 3 1 on the day The chart below shows the one year performance of BLUE
BLUE,BLUE:UW,BBG004KB4FS6,"Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc.",2016-10-26 15:15:18 +0000,http://www.fool.com/investing/2016/10/25/better-buy-celldex-therapeutics-inc-vs-bluebird-bi.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc."
BLUE,BLUE:UW,BBG004KB4FS6,Why Global Blood Therapeutics Inc.'s Shares Are Soaring Today,2016-10-25 18:26:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BT7T6nnDl_Q/why-global-blood-therapeutics-incs-shares-are-soaring-today-cm698081,Image source Getty Images What happened Shares of Global Blood Therapeutics NASDAQ GBT 160 aclinical stage biotech focused on 160 blood based disorders rose by 12 as of 11 45 a m EDT on Tuesday So what The jump can be traced to the
BLUE,BLUE:UW,BBG004KB4FS6,Why Global Blood Therapeutics Inc.'s Shares Are Soaring Today,2016-10-25 16:34:53 +0000,http://www.fool.com/investing/2016/10/25/why-global-blood-therapeutics-inc-shares-are-soari.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Global Blood Therapeutics Inc.'s Shares Are Soaring Today
BLUE,BLUE:UW,BBG004KB4FS6,"Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc.",2016-10-25 16:25:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7xbRuE2WOxk/better-buy-celldex-therapeutics-inc-vs-bluebird-bio-inc-cm697849,Image source Getty Images Pipeline vs pipeline That s the match up investors must consider when deciding which clinical stage biotech stock to buy Two such biotech stocks attracting plenty of investor attention are Celldex Therapeutics NASDAQ CLDX and bluebird
BLUE,BLUE:UW,BBG004KB4FS6,"Commit To Purchase bluebird bio At $30, Earn 14% Using Options",2016-10-20 17:25:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jEDuVH-l2nM/commit-to-purchase-bluebird-bio-at-30-earn-14-using-options-cm696063,Investors considering a purchase of bluebird bio Inc Symbol BLUE shares but cautious about paying the going market price of 53 20 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
BLUE,BLUE:UW,BBG004KB4FS6,"ETF’s with exposure to bluebird bio, Inc. : October 19, 2016",2016-10-19 15:06:19 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-bluebird-bio-inc-october-19-2016/,"ETF’s with exposure to bluebird bio, Inc. : October 19, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : October 17, 2016",2016-10-17 12:49:16 +0000,http://www.capitalcube.com/blog/index.php/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bearish-manner-blue-us-october-17-2016/,"bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : October 17, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,Why Shares of bluebird bio Inc Took a Dive Today,2016-10-14 21:42:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sSEm8c5tNOM/why-shares-of-bluebird-bio-inc-took-a-dive-today-cm693688,Image source Getty Images What happened bluebird bio NASDAQ BLUE closed down 13 Friday after presenting an update on its LentiGlobin programs and other research and development projects at its Gene Therapy Day yesterday So what R amp D days are supposed to be a
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Shares End Friday's Session Down 13%,2016-10-14 21:27:00 +0000,https://www.thestreet.com/story/13851455/1/bluebird-bio-showcases-upgraded-gene-therapy-for-rare-blood-diseases.html?puc=yahoo&cm_ven=YAHOO,Bluebird Bio Shares End Friday's Session Down 13%
BLUE,BLUE:UW,BBG004KB4FS6,"Friday's ETF Movers: IGV, XBI",2016-10-14 20:41:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KGfoi1eubeA/fridays-etf-movers-igv-xbi-cm693645,In trading on Friday the iShares North American Tech Software ETF IGV is outperforming other ETFs up about 0 9 on the day Components of that ETF showing particular strength include shares of Salesforce com CRM up about 6 3 and shares of ACI Worldwide ACIW up about 1 9 on
BLUE,BLUE:UW,BBG004KB4FS6,Why Shares of bluebird bio Inc Took a Dive Today,2016-10-14 20:24:02 +0000,http://www.fool.com/investing/2016/10/14/why-shares-of-bluebird-bio-inc-took-a-dive-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Shares of bluebird bio Inc Took a Dive Today
BLUE,BLUE:UW,BBG004KB4FS6,"Health Care Sector Update for 10/14/2016: BLUE,ENZ,EGLT",2016-10-14 20:20:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZzqZlDHzJw4/health-care-sector-update-for-10142016-blueenzeglt-cm693664,Top Health Care StocksTop Health Care Stocks JNJ 0 24 JNJ 0 24 PFE 0 11 PFE 0 11 MRK 0 26 MRK 0 26 ABT 0 34 ABT 0 34 AMGN 1 11 AMGN 1 11 Health care stocks were finishing moderately lower on Friday with the NYSE Health Care Index sinking about 0 4 while shares of health
BLUE,BLUE:UW,BBG004KB4FS6,"Friday Sector Laggards: Drugs, Biotechnology Stocks",2016-10-14 19:40:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NgC01eXFaCg/friday-sector-laggards-drugs-biotechnology-stocks-cm693617,In trading on Friday drugs shares were relative laggards down on the day by about 1 8 Helping drag down the group were shares of Auris Medical Holding EARS off about 12 1 and shares of Proteostasis Therapeutics PTI off about 9 7 on the day Also lagging the market Friday
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Shares Down 10%; Cantor Downgrades Stock To Sell,2016-10-14 15:56:18 +0000,http://finance.yahoo.com/news/bluebird-bio-shares-down-10-155618209.html,Bluebird Bio Shares Down 10%; Cantor Downgrades Stock To Sell
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird's Gene Therapy Is Firing On All Cylinders,2016-10-14 12:41:46 +0000,http://finance.yahoo.com/news/bluebirds-gene-therapy-firing-cylinders-124146946.html,Bluebird's Gene Therapy Is Firing On All Cylinders
BLUE,BLUE:UW,BBG004KB4FS6,Better Buy: bluebird bio vs. Inovio Pharmaceuticals,2016-10-13 16:44:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z20AbyPTb5o/better-buy-bluebird-bio-vs-inovio-pharmaceuticals-cm692952,Image source Getty Images The second half of 2016 appears to be turning out quite differently from the first half of the year for two clinical stage biotechs Shares of bluebird bio NASDAQ BLUE slid more than 30 by the middle of 2016 while shares of Inovio
BLUE,BLUE:UW,BBG004KB4FS6,Better Buy: bluebird bio vs. Inovio Pharmaceuticals,2016-10-13 14:42:21 +0000,http://www.fool.com/investing/2016/10/13/better-buy-bluebird-bio-vs-inovio-pharmaceuticals.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: bluebird bio vs. Inovio Pharmaceuticals
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Provides Update on LentiGlobin™ Programs and Research and Development Strategy at Gene Therapy Day,2016-10-13 12:20:04 +0000,http://www.publicnow.com/view/C4E18234CC69112BA8A17C3C557E7F9C73EB4D8F,[at noodls] - - Consistently demonstrated improved vector copy number (VCN) in transfusion-dependent β-thalassemia (TDT)and severe sickle cell disease (SCD) patient cells in vitro with manufacturing Process 2 - -Implementing ...
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-10-13 12:16:07 +0000,http://biz.yahoo.com/e/161013/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BLUE,BLUE:UW,BBG004KB4FS6,"Why bluebird bio, Inc. Stock Soared 37.4% in September",2016-10-11 13:19:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fCIV_cdLgeM/why-bluebird-bio-inc-stock-soared-374-in-september-cm691466,Image source Getty Images What happened Shares of bluebird bio Inc NASDAQ BLUE 160 a clinical stage biotech developing gene therapies caught an updraft last month The stock rose 37 4 in October according to data from S amp P Global Market Intelligence
BLUE,BLUE:UW,BBG004KB4FS6,"Why bluebird bio, Inc. Stock Soared 37.4% in September",2016-10-11 11:27:53 +0000,http://www.fool.com/investing/2016/10/11/why-bluebird-bio-inc-stock-soared-374-in-september.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why bluebird bio, Inc. Stock Soared 37.4% in September"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio Announces Topics for Gene Therapy Day, October Investor Presentation",2016-10-06 12:39:06 +0000,http://www.publicnow.com/view/E208BC7B7B97EAB0B7B50D038AFCE5780BA83DF9,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases ..."
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events",2016-10-05 21:17:37 +0000,http://biz.yahoo.com/e/161005/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events"
BLUE,BLUE:UW,BBG004KB4FS6,Peek Under The Hood: IYY Has 10% Upside,2016-10-05 14:44:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5hCJ3AeWOdw/peek-under-the-hood-iyy-has-10-upside-cm689028,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BLUE,BLUE:UW,BBG004KB4FS6,"Focus on Bluebird Bio, Not Vertex, J.P. Morgan Says",2016-10-04 17:04:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/04/focus-on-bluebird-bio-not-vertex-j-p-morgan-says/?mod=yahoobarrons&ru=yahoo,"Focus on Bluebird Bio, Not Vertex, J.P. Morgan Says"
BLUE,BLUE:UW,BBG004KB4FS6,"XBI, SRPT, IONS, BLUE: ETF Inflow Alert",2016-10-03 16:43:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i9IER0FKb-Q/xbi-srpt-ions-blue-etf-inflow-alert-cm687842,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 112 7 million dollar inflow that s a 4 5 increase week over week in outstanding
BLUE,BLUE:UW,BBG004KB4FS6,Swiss biotech giant to more than double footprint in Houston suburb,2016-09-29 18:00:11 +0000,http://www.bizjournals.com/houston/news/2016/09/29/swiss-biotech-giant-to-more-than-double-footprint.html?ana=yahoo,Swiss biotech giant to more than double footprint in Houston suburb
BLUE,BLUE:UW,BBG004KB4FS6,"Maxim Raises Target On bluebird bio From $85 To $100, Maintains Buy Rating",2016-09-29 15:53:12 +0000,http://finance.yahoo.com/news/maxim-raises-target-bluebird-bio-155312279.html,"Maxim Raises Target On bluebird bio From $85 To $100, Maintains Buy Rating"
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-09-29 12:08:28 +0000,http://biz.yahoo.com/e/160929/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BLUE,BLUE:UW,BBG004KB4FS6,Medigene AG: bluebird bio and Medigene establish strategic T cell receptor (TCR) alliance in cancer immunotherapy,2016-09-29 06:40:10 +0000,http://www.publicnow.com/view/E82456C3A6C543A37BDE7253ACC21DC7C0D1F177,"[at noodls] - 29/09/16 08:11 T cell receptor (TCR) therapeutic candidates against four targets to be generated using Medigene's proprietary TCR technology platform and bluebird bio's lentiviral vector, genome editing, ..."
BLUE,BLUE:UW,BBG004KB4FS6,Ad hoc: bluebird bio and Medigene establish strategic T cell receptor (TCR) alliance in cancer immunotherapy,2016-09-29 06:40:10 +0000,http://www.publicnow.com/view/B1602722DB6FC83580B98F3C6A8D7B1A75A87084,"[at noodls] - 29/09/16 08:10 Martinsried/Munich and Cambridge, MA, 29 September 2016. Medigene AG (MDG1, Frankfurt, Prime Standard), Germany, and bluebird bio, Inc. (Nasdaq: BLUE), USA, today announced the signing of ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio and Medigene Establish Strategic T Cell Receptor (TCR) Alliance in Cancer Immunotherapy,2016-09-29 06:30:01 +0000,http://www.publicnow.com/view/F51C4F955552576E603F83C6D51FBCCC039A2AA9,"[at noodls] - http://www.businesswire.com/news/home/20160928006578/en/ 'We are delighted to collaborate with bluebird bio, a leader in the field of cell and gene therapy, including cancer immunotherapy,' said Dolores ..."
BLUE,BLUE:UW,BBG004KB4FS6,"'Mad Money' Lightning Round: Buy, Buy, Buy Advanced Micro Devices",2016-09-24 13:00:00 +0000,https://www.thestreet.com/story/13672744/1/mad-money-lightning-round-buy-buy-buy-advanced-micro-devices.html?puc=yahoo&cm_ven=YAHOO,"'Mad Money' Lightning Round: Buy, Buy, Buy Advanced Micro Devices"
BLUE,BLUE:UW,BBG004KB4FS6,Cramer Remix: Presidential debate won't be good for business,2016-09-23 22:57:52 +0000,http://www.cnbc.com/id/103965356?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103965356,Cramer Remix: Presidential debate won't be good for business
BLUE,BLUE:UW,BBG004KB4FS6,[$$] Abeona Expands Opportunity With Partnerships,2016-09-23 20:08:00 +0000,http://www.barrons.com/articles/abeona-expands-opportunity-with-partnerships-1474661316?mod=yahoobarrons&ru=yahoo,[$$] Abeona Expands Opportunity With Partnerships
BLUE,BLUE:UW,BBG004KB4FS6,"XBI, SRPT, BLUE, IONS: ETF Inflow Alert",2016-09-23 16:21:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4eu9Cset0OI/xbi-srpt-blue-ions-etf-inflow-alert-cm683799,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 203 3 million dollar inflow that s a 8 4 increase week over week in outstanding
BLUE,BLUE:UW,BBG004KB4FS6,"Health Care Sector Update for 09/22/2016: AAAP,AVXL,BLUE",2016-09-22 21:20:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RTjvEt_6JUU/health-care-sector-update-for-09222016-aaapavxlblue-cm683461,Top Health Care StocksTop Health Care Stocks JNJ 0 46 JNJ 0 46 PFE 0 38 PFE 0 38 MRK 0 72 MRK 0 72 ABT 0 51 ABT 0 51 AMGN 1 02 AMGN 1 02 Health care stocks advanced Thursday with the NYSE Health Care Index rising about 0 7 while shares of health care companies in the S amp P
BLUE,BLUE:UW,BBG004KB4FS6,"Health Care Sector Update for 09/22/2016: LGND,AVXL,BLUE",2016-09-22 19:40:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tdIuSTIBwls/health-care-sector-update-for-09222016-lgndavxlblue-cm683387,Top Health Care StocksTop Health Care Stocks JNJ 0 44 JNJ 0 44 PFE 0 31 PFE 0 31 MRK 0 74 MRK 0 74 ABT 0 53 ABT 0 53 AMGN 0 77 AMGN 0 77 Health care stocks were increasing today with the NYSE Health Care Index rising about 0 7 while shares of health care companies in the S amp
BLUE,BLUE:UW,BBG004KB4FS6,LentiGlobin™ Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency’s PRIME Program,2016-09-21 12:51:02 +0000,http://www.publicnow.com/view/E777425754A4F9F12CE81BCC5FF0F19870DCE634,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 21, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases ..."
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-09-21 12:41:15 +0000,http://biz.yahoo.com/e/160921/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BLUE,BLUE:UW,BBG004KB4FS6,"Why Bluebird Bio Inc (BLUE), Fitbit Inc (FIT) and Goodyear Tire & Rubber Co (GT) Are 3 of Today’s Best Stocks",2016-09-16 17:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yirAIDCqDxQ/why-bluebird-bio-inc-blue-fitbit-inc-fit-and-goodyear-tire-rubber-co-gt-are-3-of-todays-best-stocks-cm680309,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Stocks received a robust lift from a falling dollar and lower Treasuries on speculation that the Federal Reserve won t raise interest rates after next week s FOMC
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio (BLUE) in Focus: Stock Moves 11.4% Higher,2016-09-16 14:22:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xjCo8x7ybQE/bluebird-bio-blue-in-focus-stock-moves-114-higher-cm680466,bluebird bio Inc BLUE was a big mover last session as its shares rose a little over 11 on the day The move came after the company was added to the prized Conviction Buy list at Goldman Sachs This led to far more shares changing hands than in a normal session This breaks the recent trend
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio (BLUE) in Focus: Stock Moves 11.4% Higher,2016-09-16 12:25:12 +0000,http://finance.yahoo.com/news/bluebird-bio-blue-focus-stock-122512579.html,bluebird bio (BLUE) in Focus: Stock Moves 11.4% Higher
BLUE,BLUE:UW,BBG004KB4FS6,"Why Cirrus Logic, bluebird bio, and GoPro Jumped Today",2016-09-15 23:17:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-YyELHfwi-o/why-cirrus-logic-bluebird-bio-and-gopro-jumped-today-cm680286,Image source GoPro The stock market s roller coaster ride continued on Thursday and investors ended up seeing gains of 1 or more in most of their favorite market benchmarks Once again much of the attention in the market centered on the Federal Reserve and some sluggish
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc. Jumped Again Today,2016-09-15 22:18:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D5c8PriA514/why-bluebird-bio-inc-jumped-again-today-cm680270,Image source Getty Images What happened bluebird bio NASDAQ BLUE continues its flight upward Monday it advanced on no apparent news and it s up 11 5 today as of 3 45 p m EDT Today s move at least has some news tied to it Goldman Sachs put the company on its
BLUE,BLUE:UW,BBG004KB4FS6,"Why Cirrus Logic, bluebird bio, and GoPro Jumped Today",2016-09-15 21:32:00 +0000,http://www.fool.com/investing/2016/09/15/why-cirrus-logic-bluebird-bio-and-gopro-jumped-tod.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Cirrus Logic, bluebird bio, and GoPro Jumped Today"
BLUE,BLUE:UW,BBG004KB4FS6,Aerie Pharmaceuticals Skyrockets On Eye Drug News,2016-09-15 20:42:19 +0000,http://www.investors.com/news/technology/aerie-pharmaceuticals-skyrockets-on-eye-drug-news/,Aerie Pharmaceuticals Skyrockets On Eye Drug News
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc. Jumped Again Today,2016-09-15 20:31:37 +0000,http://www.fool.com/investing/2016/09/15/why-bluebird-bio-inc-jumped-again-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why bluebird bio Inc. Jumped Again Today
BLUE,BLUE:UW,BBG004KB4FS6,"XBI, IONS, MDVN, BLUE: ETF Inflow Alert",2016-09-15 20:18:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cAirvSOc0FM/xbi-ions-mdvn-blue-etf-inflow-alert-cm680012,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 115 2 million dollar inflow that s a 5 4 increase week over week in outstanding
BLUE,BLUE:UW,BBG004KB4FS6,"Bluebird Bio (BLUE) Stock Jumping, Goldman Adds to Conviction Buy List",2016-09-15 18:46:00 +0000,https://www.thestreet.com/story/13741948/1/bluebird-bio-blue-stock-jumping-goldman-adds-to-conviction-buy-list.html?puc=yahoo&cm_ven=YAHOO,"Bluebird Bio (BLUE) Stock Jumping, Goldman Adds to Conviction Buy List"
BLUE,BLUE:UW,BBG004KB4FS6,"3 Stocks to Watch Thursday: Viacom, Inc. (VIAB), Aerie Pharmaceuticals Inc (AERI) and Bluebird Bio Inc (BLUE)",2016-09-15 15:19:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AcPONEzys2A/3-stocks-to-watch-thursday-viacom-inc-viab-aerie-pharmaceuticals-inc-aeri-and-bluebird-bio-inc-blue-cm679968,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Tech stocks rose 0 6 yesterday which was a bright spot among what was otherwise a dreary day for U S equities The S amp P 500 fell 0 1 the Dow Jones Industrial Average lost 0
BLUE,BLUE:UW,BBG004KB4FS6,"Goldman Sees Bluebird Bio Preparing For Flight (115% Upside), Adds To 'Conviction Buy' List",2016-09-15 13:03:52 +0000,http://finance.yahoo.com/news/goldman-sees-bluebird-bio-preparing-130352521.html,"Goldman Sees Bluebird Bio Preparing For Flight (115% Upside), Adds To 'Conviction Buy' List"
BLUE,BLUE:UW,BBG004KB4FS6,"Top Analyst Upgrades and Downgrades: Apple, AT&T, Autodesk, Bluebird Bio, Monsanto, Sarepta and More",2016-09-15 12:55:09 +0000,http://247wallst.com/investing/2016/09/15/top-analyst-upgrades-and-downgrades-apple-att-autodesk-bluebird-bio-monsanto-sarepta-and-more/,"Top Analyst Upgrades and Downgrades: Apple, AT&T, Autodesk, Bluebird Bio, Monsanto, Sarepta and More"
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Inc. (BLUE) Has Broken Out To A 9-Month High,2016-09-15 09:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jvaSCwrvqmU/bluebird-bio-inc-blue-has-broken-out-to-a-9month-high-20160915-00606,Bluebird Bio Inc. (BLUE) Has Broken Out To A 9-Month High
BLUE,BLUE:UW,BBG004KB4FS6,Here's a Reason Why Bluebird Bio (BLUE) Stock Is Jumping Today,2016-09-14 18:50:00 +0000,https://www.thestreet.com/story/13733621/1/here-s-a-reason-why-bluebird-bio-blue-stock-is-jumping-today.html?puc=yahoo&cm_ven=YAHOO,Here's a Reason Why Bluebird Bio (BLUE) Stock Is Jumping Today
BLUE,BLUE:UW,BBG004KB4FS6,8 Risky Stocks That Are Worth the Risk,2016-09-13 13:47:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cZl6TfnE6Z0/8-risky-stocks-that-are-worth-the-risk-cm678484,Want big returns Take on big risks So goes the inescapable calculus of investing With so many investors focused on safety and income these days we decided to take a contrarian approach by looking for risky companies that have the potential to deliver big payoffs We ve
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc. Jumped Monday,2016-09-12 22:47:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EKRrT2jvQ9c/why-bluebird-bio-inc-jumped-monday-cm678339,Image source Getty Images What happened bluebird bio NASDAQ BLUE ended Monday up 10 on no apparent news at least none that came today So what The spike might be a carryover from last week when the biotech announced that it was starting a phase 3 trial
BLUE,BLUE:UW,BBG004KB4FS6,Why bluebird bio Inc. Jumped Monday,2016-09-12 20:55:09 +0000,http://www.fool.com/investing/2016/09/12/why-bluebird-bio-inc-jumped-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why bluebird bio Inc. Jumped Monday
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Stock Up on Start of Phase III LentiGlobin Study,2016-09-09 16:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jwZd4717fRE/bluebird-bio-stock-up-on-start-of-phase-iii-lentiglobin-study-cm676993,bluebird bio Inc BLUE announced the commencement of a phase III study on its experimental gene therapy LentiGlobin which will incorporate an improved manufacturing process to increase transduction efficiency in patients with transfusion dependent beta thalassemia a rare blood
BLUE,BLUE:UW,BBG004KB4FS6,"3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August",2016-09-09 16:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GS4sTUgfaFs/3-reasons-bluebird-bio-inc-stock-dipped-137-in-august-cm676996,Image source Getty Images What Shares of bluebird bio Inc NASDAQ BLUE 160 a clinical stage biotech developing cellular therapies fell 13 7 in August according to data from S amp P Global Market Intelligence A larger than expected loss in the second
BLUE,BLUE:UW,BBG004KB4FS6,"3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August",2016-09-09 14:24:51 +0000,http://www.fool.com/investing/2016/09/09/3-reasons-bluebird-bio-inc-stock-dipped-137-in-aug.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Stock Up on Start of Phase III LentiGlobin Study,2016-09-09 14:02:02 +0000,http://finance.yahoo.com/news/bluebird-bio-stock-start-phase-140202241.html,bluebird bio Stock Up on Start of Phase III LentiGlobin Study
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Webcast of Gene Therapy Day,2016-09-09 12:50:05 +0000,http://www.publicnow.com/view/C668A5D6471DF2D58F5B5429AE86FE820CDD7C70,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 9, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases ..."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio: Let the Trials Begin!,2016-09-08 18:24:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/08/bluebird-bio-let-the-trials-begin/?mod=yahoobarrons&ru=yahoo,Bluebird Bio: Let the Trials Begin!
BLUE,BLUE:UW,BBG004KB4FS6,"Bluebird Improves Its Gene Therapy, Removing an Investor Concern",2016-09-08 14:36:00 +0000,https://www.thestreet.com/story/13698588/1/bluebird-improves-its-gene-therapy-removing-an-investor-concern.html?puc=yahoo&cm_ven=YAHOO,"Bluebird Improves Its Gene Therapy, Removing an Investor Concern"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Opens Phase 3 Study of LentiGlobin™ Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia,2016-09-08 12:39:03 +0000,http://www.publicnow.com/view/B1E43294353189097E67FD3FE14B4F40B2992FF1,"[at noodls] - -- HGB-207 trial to be conducted with enhancements to transduction process under the same IND as previous studies of LentiGlobin -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 8, 2016-- bluebird bio, Inc. ..."
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-09-08 12:30:39 +0000,http://biz.yahoo.com/e/160908/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird Bio Inc. (BLUE) Is Climbing In Early Trade,2016-09-08 10:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3Z70F6JNUH4/bluebird-bio-inc-blue-is-climbing-in-early-trade-20160908-00725,Bluebird Bio Inc. (BLUE) Is Climbing In Early Trade
BLUE,BLUE:UW,BBG004KB4FS6,"Oncorus®, Inc. Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., as President and Chief Business Officer",2016-09-07 14:17:00 +0000,http://finance.yahoo.com/news/oncorus-inc-appoints-biotech-industry-141700679.html,"[PR Newswire] - CAMBRIDGE, Mass., Sept. 7, 2016 /PRNewswire/ -- Oncorus®, Inc., a new immuno-oncology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme, today announced the appointment of Cyrus D. Mozayeni, M.D., as President and Chief Business Officer. Dr. Mozayeni will provide strategic leadership for the company, as well as have responsibility for corporate development, finance, legal, human resources and business operations. Dr. Mozayeni will report to Mitchell H. Finer, Ph.D., Oncorus' Chief Executive Officer and Chief Scientific Officer."
BLUE,BLUE:UW,BBG004KB4FS6,Seagate Technology (STX) Has Climbed To Over A 5-Month High,2016-09-07 10:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WRXusnI5PYs/seagate-technology-stx-has-climbed-to-over-a-5month-high-20160907-00795,Seagate Technology (STX) Has Climbed To Over A 5-Month High
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : September 1, 2016",2016-09-01 12:18:38 +0000,http://www.capitalcube.com/blog/index.php/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bearish-manner-blue-us-september-1-2016/,"bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : September 1, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,"Novartis Disbands Cell Therapy Unit; What's Ahead For Kite, Juno?",2016-08-31 17:32:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/31/novartis-disbands-cell-therapy-unit-whats-ahead-for-kite-juno/?mod=yahoobarrons&ru=yahoo,"Novartis Disbands Cell Therapy Unit; What's Ahead For Kite, Juno?"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Four Upcoming Conferences,2016-08-30 12:30:00 +0000,http://finance.yahoo.com/news/bluebird-bio-present-four-upcoming-123000346.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunothe"
BLUE,BLUE:UW,BBG004KB4FS6,We Did The Math BBH Can Go To $136,2016-08-26 12:46:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jGoHDMYlrn4/we-did-the-math-bbh-can-go-to-136-cm670448,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
BLUE,BLUE:UW,BBG004KB4FS6,Notable Two Hundred Day Moving Average Cross - BLUE,2016-08-24 23:39:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sTsmsWecjlY/notable-two-hundred-day-moving-average-cross-blue-cm669824,"In trading on Wednesday, shares of bluebird bio Inc (Symbol BLUE) crossed below their 200 day moving average of $51.93, changing hands as low as $49.95 per share. bluebird bio Inc shares are currently trading off about 8.5% on"
BLUE,BLUE:UW,BBG004KB4FS6,"ETF’s with exposure to bluebird bio, Inc. : August 23, 2016",2016-08-23 15:26:58 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-bluebird-bio-inc-august-23-2016/,"ETF’s with exposure to bluebird bio, Inc. : August 23, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,"XBI, IONS, SRPT, BLUE: ETF Outflow Alert",2016-08-22 16:40:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qy3_oguYklg/xbi-ions-srpt-blue-etf-outflow-alert-cm668478,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol XBI) where we have detected an approximate $160.7 million dollar outflow"
BLUE,BLUE:UW,BBG004KB4FS6,"ETF’s with exposure to bluebird bio, Inc. : August 12, 2016",2016-08-12 18:10:28 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-bluebird-bio-inc-august-12-2016/,"ETF’s with exposure to bluebird bio, Inc. : August 12, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,"XBI, IONS, SRPT, BLUE: ETF Inflow Alert",2016-08-12 16:49:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/--DhNSXf-v4/xbi-ions-srpt-blue-etf-inflow-alert-cm664745,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol XBI) where we have detected an approximate $216.8 million dollar inflow"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016",2016-08-11 14:32:43 +0000,http://www.capitalcube.com/blog/index.php/bluebird-bio-inc-blue-us-earnings-analysis-q2-2016-by-the-numbers-august-11-2016/,"bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Inc. Earnings: Waiting for Data,2016-08-09 21:56:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x1gAc2WHc5E/bluebird-bio-inc-earnings-waiting-for-data-cm662873,"Image source  Getty Images.  Last week bluebird bio Inc. (NASDAQ  BLUE) released its second quarter earnings report. As is common, the biotech's management held no conference call  since its revenue only"
BLUE,BLUE:UW,BBG004KB4FS6,"Health Care Sector Update for 08/08/2016: PTI,MEIP,CHEK",2016-08-08 20:12:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tn5YQbChcxs/health-care-sector-update-for-08082016-ptimeipchek-cm662070,"Top Health Care Stocks JNJ 0.55% PFE 1.63% MRK 0.71% ABT 1.89% AMGN 0.87% Health care stocks were sharply lower during late Monday trading, with the NYSE Health Care Index sinking about 1.1% while shares of health care companies"
BLUE,BLUE:UW,BBG004KB4FS6,"Blue Solutions :BLUE-FR: Earnings Analysis: For the six months ended December 31, 2015 : August 8, 2016",2016-08-08 07:44:55 +0000,http://www.capitalcube.com/blog/index.php/blue-solutions-blue-fr-earnings-analysis-for-the-six-months-ended-december-31-2015-august-8-2016/,"Blue Solutions :BLUE-FR: Earnings Analysis: For the six months ended December 31, 2015 : August 8, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,[$$] Bluebird Bio's Target Price Cut to $85,2016-08-05 11:28:00 +0000,http://www.barrons.com/articles/bluebird-bios-target-price-cut-to-85-1470396494?mod=yahoobarrons&ru=yahoo,[$$] Bluebird Bio's Target Price Cut to $85
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Inc. Tumbles 9.4% After Reporting a Wider-Than-Expected Q2 Loss,2016-08-04 21:52:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cEdp2w_uNUA/bluebird-bio-inc-tumbles-94-after-reporting-a-wider-than-expected-q2-loss-cm660746,"Image source  Getty Images.  What  Shares of bluebird bio (NASDAQ  BLUE) , a clinical stage biotechnology company focused on the development of gene based therapies to treat severe and or rare"
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Wedbush PacGrow Healthcare Conference,2016-08-04 12:30:00 +0000,http://finance.yahoo.com/news/bluebird-bio-present-wedbush-pacgrow-123000379.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the Wedbush PacGrow Healthcare Conference on August 17, 2016 at 9:10 am ET."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird reports 2Q loss,2016-08-03 22:11:37 +0000,http://sg.finance.yahoo.com/news/bluebird-reports-2q-loss-221137208.html,Bluebird reports 2Q loss
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reports Second Quarter 2016 Financial Results and Recent Operational Progress,2016-08-03 20:22:01 +0000,http://www.publicnow.com/view/FBEC405341F5B290F11E068BB0BFCDFD9060D7CF,[at noodls] - - Announced long-term commercial manufacturing agreement with Lonza- - Presented data on gene editing platform at American Society of Hematology (ASH) Workshop on Genome Editing - - Received Orphan Drug ...
BLUE,BLUE:UW,BBG004KB4FS6,"BLUEBIRD BIO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi",2016-08-03 20:15:58 +0000,http://biz.yahoo.com/e/160803/blue8-k.html,"BLUEBIRD BIO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi"
BLUE,BLUE:UW,BBG004KB4FS6,3 Biotech Stocks to Buy on Sale,2016-07-30 15:24:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/afqjsDuAQgU/3-biotech-stocks-to-buy-on-sale-cm657720,"Image source  Getty Images.  Since last summer, the market has distributed indiscriminate beatings across the biotechnology industry, and companies without approved products to sell have been hardest hit. The iShares Biotechnology ETF (NASDAQ"
BLUE,BLUE:UW,BBG004KB4FS6,5 Reasons bluebird bio Inc. Took Flight Today,2016-07-27 23:25:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0lVjTdvJchw/5-reasons-bluebird-bio-inc-took-flight-today-cm656077,Image source  Getty Images.  What  bluebird bio (NASDAQ  BLUE) ended up 11.2% on no direct news about the company.  So what  While there were no press releases announcing data
BLUE,BLUE:UW,BBG004KB4FS6,BLUE Crosses Above Key Moving Average Level,2016-07-27 22:21:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l2tBZ8vggCU/blue-crosses-above-key-moving-average-level-cm656003,"In trading on Wednesday, shares of bluebird bio Inc (Symbol BLUE) crossed above their 200 day moving average of $54.80, changing hands as high as $56.31 per share. bluebird bio Inc shares are currently trading up about 11.2% on"
BLUE,BLUE:UW,BBG004KB4FS6,"Commit To Purchase bluebird bio At $30, Earn 17.7% Using Options",2016-07-22 17:08:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LnzFPnOmlvA/commit-to-purchase-bluebird-bio-at-30-earn-177-using-options-cm653421,"Investors eyeing a purchase of bluebird bio Inc (Symbol BLUE) stock, but tentative about paying the going market price of $48.97 share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract"
BLUE,BLUE:UW,BBG004KB4FS6,Surprising Analyst 12-Month Target For JKK,2016-07-21 14:14:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mEJ6ofLnjFI/surprising-analyst-12-month-target-for-jkk-cm652581,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
BLUE,BLUE:UW,BBG004KB4FS6,"Celgene (CELG), Jounce Strike Immunotherapy Collaboration",2016-07-20 16:15:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rhfn4hcryO8/celgene-celg-jounce-strike-immunotherapy-collaboration-cm651994,"Biotech company Celgene CorporationCELG continues to pursue deals in the highly lucrative immuno oncology space. In its latest deal, Celgene has paired up with Cambridge, MA based privately held company Jounce Therapeutics, Inc. covering a global strategic collaboration focused"
BLUE,BLUE:UW,BBG004KB4FS6,"Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact",2016-07-19 11:01:00 +0000,https://www.thestreet.com/story/13642864/1/celgene-jounce-therapeutics-in-early-cancer-immunotherapy-development-pact.html?puc=yahoo&cm_ven=YAHOO,"Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact"
BLUE,BLUE:UW,BBG004KB4FS6,This Could Be the Next Big Pharma Buyout,2016-07-18 19:13:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sERSuxc3jVg/this-could-be-the-next-big-pharma-buyout-cm650764,Photo source  Getty images.  Remember the days when the mindset of Big Pharma was to just do deals? It didn't matter what you did    you just had to do something.
BLUE,BLUE:UW,BBG004KB4FS6,This Could Be the Next Big Pharma Buyout,2016-07-18 17:03:00 +0000,http://www.fool.com/investing/2016/07/18/this-could-be-the-next-big-pharma-buyout.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,This Could Be the Next Big Pharma Buyout
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Presents megaTAL Genome Editing Data at American Society of Hematology (ASH) Workshop on Genome Editing,2016-07-18 12:30:00 +0000,http://finance.yahoo.com/news/bluebird-bio-presents-megatal-genome-123000742.html,"[Business Wire] - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the presentation of pre-clinical data from its megaTAL genome editing platform at the ASH Workshop on Genome Editing, held July 14-15 in Washington, D.C."
BLUE,BLUE:UW,BBG004KB4FS6,Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold,2016-07-13 11:49:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M63FbP5AiXs/comeback-for-juno-juno-stock-fda-lifts-clinical-hold-cm648409,"Is immuno oncology focused Juno Therapeutics, Inc.JUNO , set for a comeback? The company, which saw its shares falling 31.9% last week, looks poised for a recovery with the FDA removing the clinical hold on its pivotal phase II"
BLUE,BLUE:UW,BBG004KB4FS6,Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold,2016-07-13 09:46:09 +0000,http://finance.yahoo.com/news/comeback-juno-juno-stock-fda-094609304.html,Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold
BLUE,BLUE:UW,BBG004KB4FS6,Why is Juno Therapeutics (JUNO) Stock Plunging 31% Today?,2016-07-08 18:35:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KtpiEMvsORw/why-is-juno-therapeutics-juno-stock-plunging-31-today-cm646564,"On Friday, shares of biopharmaceutical company Juno Therapeutics Inc. JUNO are plunging, down around 31% as of 10 36 AM EST after three patients died in a trial for its leading cancer therapy. The U.S. Food and Drug Administration"
BLUE,BLUE:UW,BBG004KB4FS6,"Juno (JUNO) Suffers Setback, Pivotal Study on Clinical Hold",2016-07-08 14:44:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1NAb09MeLPI/juno-juno-suffers-setback-pivotal-study-on-clinical-hold-cm646333,"Immuno oncology focused company, Juno Therapeutics, Inc.JUNO , suffered a huge setback with the FDA placing a clinical hold on the company's phase II study (ROCKET) on JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic"
BLUE,BLUE:UW,BBG004KB4FS6,Juno tanks after hours,2016-07-07 21:24:00 +0000,http://finance.yahoo.com/video/juno-tanks-hours-212400572.html,Juno tanks after hours
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. – Value Analysis (NASDAQ:BLUE) : July 5, 2016",2016-07-05 16:00:13 +0000,http://www.capitalcube.com/blog/index.php/bluebird-bio-inc-value-analysis-nasdaqblue-july-5-2016/,"bluebird bio, Inc. – Value Analysis (NASDAQ:BLUE) : July 5, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,"bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : July 1, 2016",2016-07-01 12:07:43 +0000,http://www.capitalcube.com/blog/index.php/bluebird-bio-inc-breached-its-50-day-moving-average-in-a-bullish-manner-blue-us-july-1-2016/,"bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : July 1, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,"Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here",2016-07-01 11:01:00 +0000,https://www.thestreet.com/story/13626436/1/biotech-stock-mailbag-mid-year-assessment-where-we-go-from-here.html?puc=yahoo&cm_ven=YAHOO,"Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here"
BLUE,BLUE:UW,BBG004KB4FS6,141 Reasons to Love Biotech Stocks,2016-06-30 23:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_XYP8-9lWfU/141-reasons-to-love-biotech-stocks-cm643557,"Image source  Getty Images.  The biotech sector has taken a bit of a beating, down about 24% this year as measured by the iShares NASDAQ Biotechnology Index ETF , and down about 35%"
BLUE,BLUE:UW,BBG004KB4FS6,141 Reasons to Love Biotech Stocks,2016-06-30 22:21:00 +0000,http://www.fool.com/investing/2016/06/30/141-reasons-to-love-biotech-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,141 Reasons to Love Biotech Stocks
BLUE,BLUE:UW,BBG004KB4FS6,"These 3 Biotechs Are Down More Than 36% This Year, and They're Bargains",2016-06-29 12:24:00 +0000,http://www.fool.com/investing/2016/06/29/these-3-biotechs-are-down-more-than-36-this-year-a.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"These 3 Biotechs Are Down More Than 36% This Year, and They're Bargains"
BLUE,BLUE:UW,BBG004KB4FS6,Here's Why bluebird bio's Shares Dropped 10% on Monday,2016-06-28 16:57:00 +0000,http://www.fool.com/investing/2016/06/28/heres-why-bluebird-bios-shares-dropped-10-on-monda.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's Why bluebird bio's Shares Dropped 10% on Monday
BLUE,BLUE:UW,BBG004KB4FS6,Better Buy: Agenus Inc. vs. bluebird bio,2016-06-24 12:06:00 +0000,http://www.fool.com/investing/2016/06/24/better-buy-agenus-inc-vs-bluebird-bio.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Agenus Inc. vs. bluebird bio
BLUE,BLUE:UW,BBG004KB4FS6,"Blue Financial Communication SpA :BLUE-IT: Earnings Analysis: 2015 By the Numbers : June 22, 2016",2016-06-22 07:43:03 +0000,http://www.capitalcube.com/blog/index.php/blue-financial-communication-spa-blue-it-earnings-analysis-2015-by-the-numbers-june-22-2016/,"Blue Financial Communication SpA :BLUE-IT: Earnings Analysis: 2015 By the Numbers : June 22, 2016"
BLUE,BLUE:UW,BBG004KB4FS6,"Lonza and bluebird bio, Inc., Establish a Long-term Commercial Manufacturing Agreement for Lenti-D™ and LentiGlobin™ Drug Products",2016-06-09 05:29:07 +0000,http://www.publicnow.com/view/FE0B096CC94A247B03F9639309CCACD8EB3BE28D,"[at noodls] - Basel (CH) and Cambridge, MA (USA), 9 June 2016 - Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and bluebird bio, Inc., a clinical-stage company committed to developing ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Goldman Sachs 37th Annual Healthcare Conference,2016-05-23 12:46:06 +0000,http://www.publicnow.com/view/01D3F54E6954EA3B298BD8A46C1B14574EF5AA25,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 23, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting,2016-05-09 12:58:05 +0000,http://www.publicnow.com/view/C7A3FA124026A827805B1D672DBB5BA8F5D014B3,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2016-- bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare ..."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird reports 1Q loss,2016-05-04 21:53:30 +0000,http://sg.finance.yahoo.com/news/bluebird-reports-1q-loss-215330834.html,Bluebird reports 1Q loss
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress,2016-05-04 20:20:10 +0000,http://www.publicnow.com/view/90F60AAEEFE08D8621FE74DFB456F72A0771B46B,[at noodls] - - Presented interim clinical data from Starbeam study of Lenti-D in cerebral adrenoleukodystrophy (CALD) at American Academy of Neurology (AAN) Annual Meeting - - Ten abstracts accepted for presentation ...
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at Two Upcoming Investor Conferences,2016-04-27 12:46:26 +0000,http://www.publicnow.com/view/E436E87910AE379513B07BF6D891172B8EA3FF53,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 27, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reports Interim Clinical Data from Starbeam Study of Lenti-D™ at AAN 2016 Annual Meeting,2016-04-20 13:11:11 +0000,http://www.publicnow.com/view/71FBBD0AAAD29E94F179C630BE3F3344693B9452,"[at noodls] - First clinical data to be presented from Phase 2/3 Starbeam Study; Company to host investor webcast and conference call today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 20, 2016-- bluebird ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting,2016-04-18 20:17:10 +0000,http://www.publicnow.com/view/FAD7F5799B14D7F63101EBACD9C1970623DB4449,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare ..."
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird reports 4Q loss,2016-02-24 22:21:53 +0000,http://sg.finance.yahoo.com/news/bluebird-reports-4q-loss-222153017.html,Bluebird reports 4Q loss
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to Present at the 34th Annual J.P. Morgan Healthcare Conference,2016-01-05 13:29:18 +0000,http://www.noodls.com/view/4050D9BBC7405FFAD61ACE1906FD6466237C575C,"[at noodls] - --(BUSINESS WIRE)--Jan. 5, 2016-- (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reports New Beta-thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 and HGB-206 Studies of LentiGlobin® at ASH Annual Meeting,2015-12-06 14:19:23 +0000,http://www.noodls.com/view/3E6A72E72862FC5A7906FEF78134E9143F14D148,"[at noodls] - Two patients with beta-thalassemia major with β 0 /β E genotype remain transfusion-independent for 23.4 and 20.1 months, respectively Patient with severe sickle cell disease (SCD) in HGB-205 study remainsfree ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Presents Pre-Clinical and Manufacturing Data from CAR T Oncology Programs at ASH Annual Meeting,2015-12-06 14:19:23 +0000,http://www.noodls.com/view/089D64C940E6B585020AEADFA0888B36262ACA14,"[at noodls] - Company to webcast investor event, Sunday, December 6 at 8:30 p.m. ET ORLANDO, Fla.--(BUSINESS WIRE)--Dec. 6, 2015-- bluebird bio, Inc. (NASDAQ:BLUE), a clinical-stage company committed to developing potentially ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reports New Beta-thalassemia Major Data from Northstar Study of LentiGlobin® at ASH Annual Meeting,2015-12-05 13:06:26 +0000,http://www.noodls.com/view/9C6A7DA618EF22EF66CD300C00D74823F5013311,[at noodls] - Transfusion independence observed in patients with non-β 0 /β 0 genotypes Transfusion reduction between 33 percent and 100 percent observed in patients with β 0 /β 0 genotype ... This is an abstract of ...
BLUE,BLUE:UW,BBG004KB4FS6,ViroMed and bluebird bio Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy,2015-12-04 02:53:31 +0000,http://www.noodls.com/view/0026BCA698804E04C80B2AFA245D7EF83004B9F7,"[at noodls] - bluebird bio and ViroMed Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy Cambridge, Mass. and Seoul, Korea - December 3, 2015 -- bluebird bio, Inc. ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio and ViroMed Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy,2015-12-03 13:19:32 +0000,http://www.noodls.com/view/F83C28903155C69F5BABAD97663CDD1E73F380CF,"[at noodls] - CAMBRIDGE, Mass. & SEOUL, Korea--(BUSINESS WIRE)--Dec. 3, 2015-- bluebird bio, Inc. (Nasdaq: BLUE) and ViroMed Co., Ltd. today announced that they have entered into an exclusive license agreement to research, ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Participation in 27th Annual Piper Jaffray Healthcare Conference,2015-11-25 13:55:23 +0000,http://www.noodls.com/view/0CF7FDEB6DE5497213C11D2B7C4971A1FFDDB3E6,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 25, 2015-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases ..."
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio to present LentiGlobin® BB305 Clinical Data and bb2121 Preclinical Data at Annual Meeting of the American Society of Hematology,2015-11-05 13:20:08 +0000,http://www.noodls.com/view/7D6128C31B205AECB18032A99D1C97615884B327,[at noodls] - - Six abstracts accepted for presentation - - Interim data on LentiGlobin in beta-thalassemia show six of six evaluable non-β 0 /β 0 patients are transfusion-independent as of July 31 st data cut-off; ...
BLUE,BLUE:UW,BBG004KB4FS6,Bluebird reports 3Q loss,2015-11-05 00:35:40 +0000,http://sg.finance.yahoo.com/news/bluebird-reports-3q-loss-003540923.html,Bluebird reports 3Q loss
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Reports Third Quarter 2015 Financial Results and Recent Operational Progress,2015-11-04 21:38:15 +0000,http://www.noodls.com/view/75BFDE3B2C1B1F586ED9AB47D1B7629FB146299A,[at noodls] - -- Six abstracts accepted for presentation at American Society of Hematology (ASH) Annual Meeting -- -- Increased enrollment target for HGB-206 study of LentiGlobin ® in severe sickle cell disease (SCD) ...
BLUE,BLUE:UW,BBG004KB4FS6,bluebird bio Announces Participation in 24th Annual Credit Suisse Healthcare Conference,2015-11-04 13:47:05 +0000,http://www.noodls.com/view/BAAA48B93B757C22D9B69D42415A33419F555FD3,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2015-- bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases ..."
BLUE,BLUE:UW,BBG004KB4FS6,"Alexandria Real Estate Equities, Inc. Announces 10-Year 253,000 RSF Full-Building Build-to-Suit Lease at 60 Binney Street for bluebird bio for Its New Office/Laboratory Headquarters in the Heart of Kendall Square in Cambridge, MA",2015-09-29 12:37:13 +0000,http://www.noodls.com/view/39ED50F85D820A04EE9A0830697C67F151978278,"[at noodls] - PASADENA, Calif., Sept. 29, 2015 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the largest and leading office REIT uniquely focused on collaborative science and technology campuses ..."
BLUE,BLUE:UW,BBG004KB4FS6,Texas Instruments tipped as chip industry's next consolidator,2015-06-19 20:25:43 +0000,http://sg.finance.yahoo.com/news/texas-instruments-tipped-chip-industrys-202543504.html,Texas Instruments tipped as chip industry's next consolidator
BLUE,BLUE:UW,BBG004KB4FS6,"BUZZ-U.S. STOCKS ON THE MOVE-Humana, Alibaba, Twitter, airline stocks",2015-04-29 18:03:31 +0000,http://uk.finance.yahoo.com/news/buzz-u-stocks-move-humana-180331388.html,"BUZZ-U.S. STOCKS ON THE MOVE-Humana, Alibaba, Twitter, airline stocks"
BLUE,BLUE:UW,BBG004KB4FS6,US STOCKS-Futures point to modest gains at the open,2015-02-02 13:51:14 +0000,http://uk.finance.yahoo.com/news/us-stocks-futures-point-modest-135114930.html,US STOCKS-Futures point to modest gains at the open
BLUE,BLUE:UW,BBG004KB4FS6,"US STOCKS-S&P 500 erases early losses to end flat; energy, tech up",2014-12-09 21:53:04 +0000,http://uk.finance.yahoo.com/news/us-stocks-p-500-erases-215304375.html,"US STOCKS-S&P 500 erases early losses to end flat; energy, tech up"
BLUE,BLUE:UW,BBG004KB4FS6,"US STOCKS-Dow, S&P 500 edge down on global worries; Nasdaq climbs",2014-12-09 20:05:46 +0000,http://uk.finance.yahoo.com/news/us-stocks-dow-p-500-200546274.html,"US STOCKS-Dow, S&P 500 edge down on global worries; Nasdaq climbs"
BLUE,BLUE:UW,BBG004KB4FS6,"US STOCKS-Dow, S&P 500 down but off day's lows; Nasdaq edges up",2014-12-09 18:38:46 +0000,http://uk.finance.yahoo.com/news/us-stocks-dow-p-500-183846842.html,"US STOCKS-Dow, S&P 500 down but off day's lows; Nasdaq edges up"
BLUE,BLUE:UW,BBG004KB4FS6,US STOCKS-Global demand worries drag Wall St lower,2014-12-09 16:30:00 +0000,http://uk.finance.yahoo.com/news/us-stocks-global-demand-worries-163000765.html,US STOCKS-Global demand worries drag Wall St lower
BLUE,BLUE:UW,BBG004KB4FS6,US open: Stocks suffer steep falls early on as global sell-off continues,2014-12-09 15:21:00 +0000,http://uk.finance.yahoo.com/news/us-open-stocks-suffer-steep-152100027.html,US open: Stocks suffer steep falls early on as global sell-off continues
BLUE,BLUE:UW,BBG004KB4FS6,US STOCKS-Wall St drops on global demand concerns,2014-12-09 15:00:28 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-drops-150028893.html,US STOCKS-Wall St drops on global demand concerns
BLUE,BLUE:UW,BBG004KB4FS6,US STOCKS-Wall St to slide at open on global demand concerns,2014-12-09 14:22:21 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-slide-142221296.html,US STOCKS-Wall St to slide at open on global demand concerns
BLUE,BLUE:UW,BBG004KB4FS6,US STOCKS-Futures decline after biggest drop since Oct,2014-12-09 13:33:23 +0000,http://uk.finance.yahoo.com/news/us-stocks-futures-decline-biggest-133323431.html,US STOCKS-Futures decline after biggest drop since Oct
BLUE,BLUE:UW,BBG004KB4FS6,US STOCKS-Futures lower after after biggest drop since Oct,2014-12-09 12:49:45 +0000,http://uk.finance.yahoo.com/news/us-stocks-futures-lower-biggest-124945605.html,US STOCKS-Futures lower after after biggest drop since Oct
BLUE,BLUE:UW,BBG004KB4FS6,Bayer bets on gene therapy with Dimension deal,2014-06-23 11:56:36 +0000,http://sg.finance.yahoo.com/news/bayer-bets-gene-therapy-dimension-115636401.html,Bayer bets on gene therapy with Dimension deal
